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Cardiovascular disease (CVD) is the leading cause of deaths worldwide. 
Prostate cancer is the most prevalent cancer in U.S. male population. Diet-induced 
hypercholesterolemia and chronic inflammation promote the development of both 
CVD and prostate cancer. Glyceollins are a group of soy phytoalexins possessing a 
variety of biological activities. This research project focused on characterizing 
glyceollins’ bioactivities in alleviating cholesterol dysregulation, prevention of 
prostate cancer, and regulating gut microbiome.  
The first part of the project aimed to evaluate glyceollins’ cholesterol-
lowering effect in-vivo. Male golden Syrian hamsters were fed high-fat diet with or 
without glyceollins supplementation for 28 days. Glyceollins supplementation led to a 
significant reduction of plasma VLDL, hepatic cholesterol esters and total lipid 
content. Consistent with changes in circulating cholesterol, glyceollins 
  
supplementation also altered expression of the genes related to cholesterol 
metabolism in the liver.  
The second part of the study aimed to evaluate glyceollins’ effect in reducing 
prostate cancer tumor growth in a xenograft model. An initial delayed appearance of 
tumor was observed in a PC-3 xenograft model. However, no difference in tumor 
sizes was observed in a LNCaP xenograft model. Extrapolation analysis of tumor 
measurements indicated that no difference in sizes was expected for both PC-3 and 
LNCaP tumors. Glyceollins had no effect on the androgen responsive pathway, its 
proliferation, cell cycle, or on angiogenesis genes in tumor and xenobiotic 
metabolism, cholesterol transport, and inflammatory cytokine genes in liver. 
Glyceollins’ low bioavailability might have led to the ineffectiveness in reducing 
tumor growth in-vivo. 
The microbiome has emerged as an important and integral part of the human 
physiology with a significant role in human health and disease. The third part of the 
study aimed to evaluate the effect of glyceollins on the gut microbiome in mice. Fecal 
and cecal samples collected from mouse feeding studies were analyzed for microbial 
population and composition. Glyceollins supplementation did not alter gut bacteria 
groups in cecal sample examined in this study. Glyceollins significantly affected total 
Enterobacteriaceae and Ruminococcus population in fecal samples collected at 24 h, 
indicating the impact and importance of time of collection in interpreting gut 
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Cardiovascular disease (CVD) has been the leading cause of death worldwide 
since the 1970s. Prostate cancer is the most prevalent cancer in U.S. male population and 
accounts for 15% of all malignant cancer incidences. Diet-induced hypercholesterolemia 
and chronic inflammation promote the development of both CVD and prostate cancer. 
Despite the prevalence and severity of these chronic conditions, effective cures remain 
largely unavailable. Hence, prevention presents an important part of overall management 
strategy for these chronic diseases. Given the role of diet in the development of CVD and 
prostate cancer, modulation of diet is key in the prevention strategy. Soy is one of the 
major agricultural commodities in the U. S. and worldwide. Soy and soy-derived foods 
are rich sources of bioactive phytochemicals and well known for their health promoting 
effects, include protection against cardiovascular diseases and cancers such as prostate 
cancer. However, the precise bioactive component(s) as well as the mechanism(s) of 
action remain largely unresolved. Glyceollins are soy phytoalexins possessing a variety 
of biological activities, including antibacterial, antifungal, antiproliferative, 
antiestrogenic, antidiabetic, antioxidant and anti-inflammatory effects. 
Hence, the overall goal of this research was to elucidate the bioactive components 
of soy and the underlay mechanisms of action, and the focus was on the examination of 
the bioactivities of the novel soy-derived compounds glyceollins. The current research 
projects characterized glyceollins’ bioactivities in alleviating cholesterol dysregulation 
resulted from consumption of a western-style diet, and glyceollins’ effect on prostate 




1) To examine the hypothesis that glyceollins can alleviate metabolic and 
inflammatory disorders resulting from high fat/cholesterol diet.  
2) To determine the hypothesis, that glyceollins possess preventative effect 
against prostate cancer. 
3) To investigate the influence of diet and glyceollins supplementation on 





Chapter 1: Literature Review 
 
1.1. Diet and chronic diseases 
A chronic disease is a human health condition or disease that is persistent or long-
lasting in effects. The World Health Organization (WHO) reported chronic conditions to 
be by far the leading cause of mortality in the world, representing 36 million deaths in 
2008 and over 63% of all deaths (WHO, 2013). Chronic illnesses cause about 60% of 
deaths in the U. S. in 2005, and CVD, cancer, chronic respiratory diseases, and diabetes 
were the four top causes of mortality in the general US population (CDC, 2009), among 
which CVD accounted for 30% of all deaths and cancer cost $263.8 billion in the U. S. in 
2010 (AACR, 2012). 
Over the past three decades, the role of diet in the prevention and control of 
morbidity and premature mortality due to chronic diseases, like CVD and cancer, has 
well been established by the vast population-based epidemiological studies (Kris-
Etherton, Eckel, Howard, St Jeor, & Bazzarre, 2001; Lichtenstein, Appel, Brands, 
Carnethon, Daniels, Franch, et al., 2006). Diet and genetic predisposition are identified to 
be the most important environmental factors in the development of chronic diseases 
(Simopoulos, 1990). Humans, as a species, have not changed genetically over the past 
tens or hundreds millenniums, however, major changes have taken place in food supply 
and diet compositions (Friend, 1990), thus diet is considered the dominant part in the 
soaring incidence of CVD and cancer (Freeman & Solomon, 2004; Spence, Jenkins, & 




cholesterol level has been well established (Spence, Jenkins, & Davignon, 2010), and 
hypercholesterolemia is strongly correlated with CVD (Kinosian, Glick, & Garland, 
1994). Doll and Peto performed an extensive review in 1981, in which they determined 
that diet is the largest risk factor of cancer and attributable to approximately 35% of 
cancer deaths in the U. S. with percentage potentially ranging as low as 10% to as high as 
70% (Doll & Peto, 1981). Willett further studied several types of cancers and estimated 
that 75% (ranging from 20% to 80%) of prostate cancer deaths are avoidable by 
modification of diet (Willett, 1995). 
 
1.1.1. Hypercholesterolemia 
Hypercholesterolemia is a condition that high levels of cholesterol present in the 
blood caused by the imbalance between cholesterol uptake and excretion (van der Wulp, 
Verkade, & Groen, 2013). Hypercholesterolemia is strongly associated with CVD, such 
as atherosclerosis, and can further lead to myocardial infarction, stroke, and peripheral 
vascular disease. The pathways involved in the development of hypercholesterolemia are 
regulated via a complex interplay of enzymes, transport proteins, transcription factors and 
non-coding RNAs (van der Wulp, Verkade, & Groen, 2013).  
 
Current understanding of cholesterol metabolism, absorption, transport, 
catabolism and excretion, and potential targets in prevention of hypercholesterolemia in 






1.1.1.1. Cholesterol metabolism 
Cholesterol is a type of sterol (Fig. 1) and building block for all mammalian cell 
membranes (Maxfield & Tabas, 2005). It is essential for proper membrane permeability 
and fluidity. Also, cholesterol serves as a precursor for the biosynthesis of steroid 
hormones, bile acids, and vitamin D (Rezen, Rozman, Pascussi, & Monostory, 2011). 
 
Fig. 1.1. Structure of cholesterol. 
 
Physiologically, cholesterol is mainly de novo synthesized in the liver (Fig18), via 
a complex 37-step process, which starts with the rate-limiting enzyme 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase (Molina, Vazquez, & Gutierrez, 1991). A 
typical individual has a daily cholesterol synthesis of ~1 g, and a total body content of 
~35 g, primarily located within the membranes of cells. Cholesterol can also be derived 
from the diet. On average, daily dietary intake of cholesterol in the U. S. is 300 - 450 mg 
(Lecerf & de Lorgeril, 2011).  
Normally, the body has the ability to compensate for additional cholesterol 
consumption by reducing cholesterol synthesis. Therefore, under physiological condition, 
cholesterol intake in food has little, if any, effect on total body cholesterol content or 
concentrations of cholesterol in the circulation. This is achieved by excreting the 




cholesterol is re-absorbed back into circulation. The remainder is lost in the feces. The 
excretion and re-absorption of bile acids are known as the enterohepatic circulation, 
which is essential for the digestion and absorption of dietary fats. 
 
Fig. 1.2. Critical enzymes involved in synthesis of cholesterol. 
 
De novo synthesis of cholesterol is regulated by the cholesterol level that is 
present in circulation (Gylling, Strandberg, Tilvis, & Miettinen, 1994; Molina, Vazquez, 
& Gutierrez, 1991). Under normal physiological conditions, higher intake of dietary 
cholesterol will lead to a decrease in endogenous production, whereas lower intake will 
induce the increase of de novo synthesis (Lecerf & de Lorgeril, 2011). Upon the 




factors will be triggered and prevent further synthesis of cholesterol (Brown & Goldstein, 
1997). Downstream, a feed-forward pathway will be activated to increase the conversion 
of cholesterol into bile acids. Additionally, excess cholesterol will be actively removed 
from peripheral and transported back to the liver for excretion via the reverse cholesterol 
transport pathway (Lewis & Rader, 2005).  
 
1.1.1.2. Potential targets in cholesterol synthesis in prevention of hypercholesterolemia  
Inhibition of HMG-CoA reductase has been proven effective in inhibiting 
cholesterol synthesis and is widely used in therapeutic treatments (Pedersen, Kjekshus, 
Berg, Haghfelt, Faergeman, Thorgeirsson, et al., 2004). The reduction of hepatic 
cholesterol synthesis in liver is compensated for by increase in cholesterol uptake from 
circulation resulting in lower plasma cholesterol levels (Ma, Gil, Südhof, Bilheimer, 
Goldstein, & Brown, 1986). Other targets involve the non-rate-limiting steps in 
cholesterol synthesis (such as CYP51 and squalene synthase) have also been studied, but 
their effectiveness in reducing cholesterol synthesis has not been proven (Korošec, 
Ačimovič, Seliškar, Kocjan, Tacer, Rozman, et al., 2008; Wasko, Smits, Shull, Wiemer, 
& Hohl, 2011).  
 
1.1.1.3. Biomarkers in cholesterol synthesis 
Sterol Regulatory Element-Binding Protein (SREBP) 1 and 2 are in charge of 
sensing of intracellular cholesterol in the endoplasmic reticulum, which is one of the 
primary mechanisms of cholesterol regulation (Lobaccaro, Repa, Lu, Caira, Henry-




and SREBP-2. SREBP-1a is responsible for stimulation of regulatory genes involved in 
both cholesterol and fatty acid synthesis, SREBP-1c stimulates lipogenesis, and SREBP-2 
is responsible for regulation of cholesterol-synthesizing enzymes and LDL receptor in 
case of cholesterol depletion (Chang, Chang, Ohgami, & Yamauchi, 2006). Non-
activated SREBPs are located at the nuclear envelope and endoplasmic reticulum 
membranes. In the presence of cholesterol, SREBP is bound to sterol regulatory element-
binding protein cleavage-activating protein (SCAP) and insulin-induced gene (Insig)-1 to 
form a complex (Fig. 20). When cholesterol levels drop, Insig-1 dissociates from the 
SREBP-SCAP complex, and the remaining complex migrates to the Golgi apparatus, 
where SCAP will activate S1P and S2P, which will then enzymatically cleave SREBP. 
After that, the cleaved SREBP migrates to the nucleus and acts as a transcription factor to 
bind to the SRE, and initiates a number of downstream events, among which are the LDL 
receptor and HMG-CoA reductase. LDL receptor binds to circulating LDL and take the 
LDL into the cell. When cholesterol levels are high, synthesis can be turned off, and both 
LDL receptor and HMG-CoA reductase expression are reduced. HMG-CoA reductase 
contains both a cytosolic domain, which is responsible for its catalytic function, and a 
membrane domain, which is more susceptible to destruction by the proteasome as 
cholesterol concentration increases (Guo, Li, Wu, Xie, Zhang, & Cui, 2008; Lagace, 
Storey, & Ridgway, 2000; Rawson, 2003; Weber, Boll, & Stampfl, 2004).  
 
1.1.1.4. Cholesterol absorption and transport 
Transport of cholesterol is an intricate process. Cholesterol is only slightly soluble 




Cholesterol in the form of free or cholesterol esters and triglycerides are mainly 
transported in the circulation within lipoproteins. Amphipathic molecules, such as 
phospholipids, are wrapped on the surface of the lipoprotein particle. Additionally, 
proteins (e. g. apolipoprotein E, apolipoprotein B100) serve as cell-targeting signaling 
molecules are also exposed on the surface. Several types of lipoproteins namely, 
chylomicrons, VLDL, IDL, LDL, and HDL, are classified according to the increasing 
density. The cholesterol within all these various lipoproteins is identical, with part of 
cholesterol carried in free form, and some carried as fatty acyl esters. Lipoproteins differ 
themselves by possessing distinct apolipoproteins so that each lipoprotein can be 
recognized by specific receptors on cell membranes. In other words, the apolipoproteins 
on the surface are molecular identifications that determine the start and end points for 
cholesterol transport. Chylomicrons carry fats from the intestine to muscle and other 
tissues that need fatty acids for energy or fat production. They are the least dense type of 
cholesterol transport molecules and contain apolipoprotein B-48, apolipoprotein C, and 
apolipoprotein E in the shells. Cholesterol that is not used by peripheral tissues remains 
in chylomicron remnants, which are more cholesterol-rich, will be taken up by the liver 
from circulation. Liver produces VLDL, which contain excess triacylglycerol and 
cholesterol. VLDLs contain apolipoprotein B100 and apolipoprotein E in the shells. After 
released into the bloodstream, triacylglycerol in VLDL are cleaved and absorbed, and the 
remaining form IDL molecules, which contain an even higher percentage of cholesterol. 
The IDL molecules can either be metabolized and directly picked up through the LDL 
receptor on the liver cell surfaces, or continue to lose triacylglycerol in the bloodstream 




within them. LDL molecules are the major carriers of cholesterol in the circulation, and 
each one contains approximately 1,500 molecules of cholesterol ester. The surface of the 
LDL molecule contains only one molecule of apolipoprotein B100, which can be 
recognized by the LDL receptor in peripheral tissues. Upon binding of apolipoprotein 
B100, LDL will be taken into the cells, and the cholesterol can be used for membrane 
biosynthesis or esterified and stored within the cell. Synthesis of the LDL receptor is 
regulated by SREBP, the same regulatory protein controlling de novo synthesis of 
cholesterol. When a cell has abundant cholesterol, LDL receptor synthesis is blocked so 
that new cholesterol in the form of LDL molecules cannot be taken up. On the other 
hand, more LDL receptors will be made if the cell is deficient in cholesterol. HDL 
particles are responsible for transporting cholesterol back to the liver for excretion or to 
other tissues that use cholesterol to synthesize hormones in a process known as reverse 
cholesterol transport. Due to the high prevalence of high circulating cholesterol in the 
western population, more HDL is usually thought to be “good” for health.  
 
1.1.1.5. Potential targets in cholesterol absorption and transport in prevention of 
hypercholesterolemia 
Despite the considerable amount of research and effort in inhibiting cholesterol 
absorption and transport, current treatments are usually nonspecific and require relatively 
high doses to achieve modest effect in lowering circulating LDL. However, recent 
findings in plant sterol/stanols, which are rich in cooking oils, wheat cereals, nuts and 
seeds and structurally similar to cholesterol, may present an alternative approach in 




comparable efficiency as cholesterol (Wang, Sun, Zhang, Ma, Xu, Belani, et al., 2006), 
and effectively lower circulating LDL levels in human (Guardamagna, Abello, Baracco, 
Federici, Bertucci, Mozzi, et al., 2011). Thus, ABCG5/8 may be a better target than LDL 
in reducing cholesterol absorption and transport. 
 
1.1.1.6. Biomarkers in cholesterol absorption and metabolism 
LXR is a member of the nuclear receptor family of transcription factors and is 
closely related to several other nuclear receptors, such as the PPARs, FXR and RXR. 
LXR can dimerize with RXR and is an important transcriptional regulator of cholesterol, 
fatty acid, and glucose homeostasis. LXR can be activated by excessive cholesterol, 
either dietary or endogenous, and 1) stimulate cholesterol removal from the cell, 
transportation to the liver and biliary excretion; 2) enhance reverse cholesterol transport; 
3) inhibit intestinal cholesterol absorption; and 4) inhibit cholesterol synthesis and uptake 
by the cells (Beltowski, 2008). Activation of the LXR/RXR heterodimer can lead to an 
increase of intestinal expression of the energy-dependent transporter protein ABCA1, 
which is critical in cellular cholesterol efflux and dietary cholesterol absorption. It 
completely blocks intestinal absorption of cholesterol (McNeish, Aiello, Guyot, Turi, 
Gabel, Aldinger, et al., 2000; Repa, Turley, Lobaccaro, Medina, Li, Lustig, et al., 2000). 
In addition to ABCA1, LXR directly regulates another two members of the ABC 
superfamily, ABCG5 and ABCG8 (Lee & Carr, 2005), which are involved in actively 
efflux cholesterol and plant sterols back into the intestinal lumen. In addition, ABCG5 
and ABCG8 located at the surface of hepatocytes can facilitate efflux of cholesterol and 




Two forms of LXR receptors (α and β) exist. LXRα plays critical a role in the control of 
cholesterol synthesis (Peet, Turley, Ma, Janowski, Lobaccaro, Hammer, et al., 1998). 
Knock-down of LXRα can significantly increase the expression of the cholesterol 
synthesis transcriptional regulator SREBP-2, as well as HMG-CoA reductase and 
synthase, FPP synthase, and SQS (Alberti, Schuster, Parini, Feltkamp, Diczfalusy, 
Rudling, et al., 2001; Peet, et al., 1998), suggesting a role of LXRα in down-regulation or 
suppression of cholesterol synthesis pathways (Millatt, Bocher, Fruchart, & Staels, 2003).  
PPARs are a group of nuclear receptor proteins that function as transcription 
factors, which play essential roles in the regulation of cellular differentiation, 
development, metabolism (carbohydrate, lipid, protein), and tumorigenesis (van Raalte, 
Li, Pritchard, & Wasan, 2004). 
PPARα plays a major role as a regulator of fatty acid catabolism and targets genes 
such as FAS, ACACA, and SREBP-1 (Ferre & Foufelle, 2010; Goldstein & Brown, 
1997). PPARα is also very important in lipoprotein metabolism, especially in the 
metabolism of triglyceride-rich lipoproteins (Staels, Dallongeville, Auwerx, Schoonjans, 
Leitersdorf, & Fruchart, 1998). Activation of PPARα in the liver will shift free fatty acid 
metabolism from triglyceride synthesis to catabolism, increase the activity of LPL (Heller 
& Harvengt, 1983), and thus reduce the secretion of VLDL particles from liver 
(Schoonjans, Staels, & Auwerx, 1996). LPL is the key enzyme in the hydrolysis of 
triglycerides and also mediates the uptake of atherogenic triglyceride-rich lipoproteins 
remnants by the liver (Schoonjans, PeinadoOnsurbe, Lefebvre, Heyman, Briggs, Deeb, et 
al., 1996; Staels, Vudac, Kosykh, Saladin, Fruchart, Dallongeville, et al., 1995). On the 




elevated VLDL production, impaired clearance of triglyceride-rich lipoproteins in the 
periphery, and increased plasma triglyceride levels (Duval, Muller, & Kersten, 2007). 
PPARα activation also up-regulates the synthesis of apo A-I and A-II, two major 
HDL apolipoproteins in the liver, and promote HDL maturation through the increased 
hydrolysis of triglyceride-rich lipoproteins. (Bisgaier, Essenburg, Barnett, Auerbach, 
Haubenwallner, Leff, et al., 1998; Vu-Dac, Chopin-Delannoy, Gervois, Bonnelye, 
Martin, Fruchart, et al., 1998; Vudac, Schoojans, Kosykh, Dallongeville, Fruchart, Staels, 
et al., 1995).  
The PPAR nuclear receptors appear to play a central role in the regulation of 
LXRα expression. Activators of both PPARα and PPARγ are shown to induce LXRα 
expression (Chawla, Boisvert, Lee, Laffitte, Barak, Joseph, et al., 2001; Chinetti, 
Lestavel, Bocher, Remaley, Neve, Torra, et al., 2001). The binding of the nuclear 
receptor PPARα to a PPAR response element (PPRE) in the 5’ flanking region of LXRα 
gene can up-regulated expression of LXRα mainly by increasing transcriptional rate 
(Laffitte, Joseph, Walczak, Pei, Wilpitz, Collins, et al., 2001; Tobin, Steineger, Alberti, 
Spydevold, Auwerx, Gustafsson, et al., 2000). PPARα up-regulation will induce ABCA1 
expression through the nuclear LXRα to promote cholesterol efflux (Chinetti, et al., 
2001). PPARα induces the hepatic expression of LXRα, then LXRα up-regulates the 
expression of CYP7A1, a protein that is key in promoting conversion of cholesterol to 
bile acids in the liver (Hafner, Rezen, & Rozman, 2011). Once LXRα is activated, LXR-
dependent pathways and genes described in the previous section will be activated and 





1.1.1.7. Cholesterol catabolism and excretion 
Cholesterol can be converted into a variety of bile acids in the liver (Javitt, 1994), 
and CYP7A1 is the key enzyme involved in bile acid synthesis (Handschin, Gnerre, 
Fraser, Martinez-Jimenez, Jover, & Meyer, 2005). Bile acids are usually conjugated with 
glycine, taurine, glucuronic acid, or sulfate. A mixture of conjugated and nonconjugated 
bile acids, along with cholesterol, is excreted from the liver into the bile. Approximately 
95% of the bile acids are re-absorbed from the intestines, and the remainder is lost in the 
feces (Wolkoff & Cohen, 2003). The excretion and re-absorption of bile acids form the 
basis of the enterohepatic circulation, which is essential for the digestion and absorption 
of dietary fats. Up to 1 g per day of cholesterol enters the colon, which may originate 
from the diet, bile, and desquamated intestinal cells, and is further metabolized by the 
colonic bacteria into a nonabsorbable sterol, coprostanol. Free cholesterol, bile acids, and 
the metabolites are then excreted in the feces. 
Cholesterol is susceptible to oxidation and can easily be oxidized into derivatives 
known as oxysterols. Three different oxidation mechanisms have been identified, which 
are 1) autoxidation, 2) secondary oxidation to lipid peroxidation, and 3) cholesterol-
metabolizing enzyme oxidation (Bosinger, Luf, & Brandl, 1993). Oxysterols can exert 
inhibitory actions on cholesterol biosynthesis (Kandutsch, Chen, & Heiniger, 1978). 
Oxysterols are also involved in bile acid biosynthesis, transport of cholesterol, and 







1.1.1.8. Diet and hypercholesterolemia 
Hypercholesterolemia is typically due to a combination of environmental and 
genetic factors, with dietary choices being an important part of the environmental factors 
(Bhatnagar, Soran, & Durrington, 2008). It is well known that diet has an important effect 
on circulating cholesterol (Howell, McNamara, Tosca, Smith, & Gaines, 1997). Dietary 
cholesterol can regulate cholesterol synthesis in humans, in which liver is the major organ 
senses the increase in uptake, and increased intake of dietary cholesterol will suppresses 
hepatic cholesterol synthesis (Stange & Dietschy, 1985; van der Wulp, Verkade, & 
Groen, 2013). In recent years, the intestine has come into focus as an important control 
point in cholesterol homeostasis, and approximately 50% of the non-esterified cholesterol 
is absorbed in the intestine (Lichtenstein, 1990). Genetic predisposition also plays a 
major role in hypercholesterolemia, potentially adding to lifestyle factors and multiplying 
the risk of late complications (Matsushima & Teramoto, 1998). 
Consumption of a western-style diet, which is generally high in fat and 
cholesterol, is associated with an increased level of cholesterol and further leads to a 
higher level of LDL in the blood. Excessive LDL that is not taken up by the peripheral 
tissues will remain in the circulation and be oxidized and taken up by macrophages. 
These macrophages will become engorged and form foam cells. Foam cells are often 
trapped in the walls of blood vessels and contribute to atherosclerotic plaque formation. 
These plaques are the main causes of heart attacks, strokes, and other serious medical 
problems. Thus, the dietary control of cholesterol level may play a critical role in the 





1.1.2. Prostate cancer 
Prostate cancer is identified as the most prevalent cancer in U.S. population in 
2011 and accounts for 15% of all malignant cancer incidences (AACR, 2012). Many 
factors, including genetics, hormones, race, age, diet, and the environment have been 
identified to be responsible for the initiation and development of prostate cancer.  
Treatment of prostate cancer generally involves surgery, various forms of 
radiation therapy, cryosurgery, with hormonal therapy and chemotherapy generally 
reserved for more advanced disease (Macpherson, Ng, Lakhani, Price, Venitz, & Figg, 
2002; Tammela, 2012). The age and underlying health of the man, the extent of 
metastasis, histology and response of the cancer to initial treatment are important in 
determining the outcome of the disease (Bostwick, Burke, Djakiew, Euling, Ho, 
Landolph, et al., 2004). However, none of these therapeutic strategies is an effective cure 
for this disease.  
The causes of prostate cancer remain largely unknown (Hsing & Chokkalingam, 
2006). In the process of understanding the initiation and progression of prostate cancer, a 
wide variety of pathways and biomarkers have been identified, which reflect changes in 
cell morphometry; DNA ploidy; chromosomal gains and losses; cytoplasmic 
differentiation; cytoskeletal proteins; cell adhesion, proliferation, and apoptosis; growth 
factors and their receptors; oncogenes and tumor suppressor genes; AR gene mutations; 







1.1.2.1. Role of steroid hormones in prostate cancer 
Androgens and estrogens are two groups of steroid hormones involved in the 
metabolism, inflammation, immune functions, and development of sexual characteristics 
(Holmes & Shalet, 1996). Aside from androgens’ physiological role, androgens also play 
an important part in prostate cancer progression and metastases (Chan, Stampfer, & 
Giovannucci, 1998; Huggins & Hodges, 1972). Estrogens are also presented in male, 
though in lower concentration. More and more evidence supports the role of estrogen in 
the regulation of prostate cancer, which may act through two different ways: 1) indirect 
androgens lowering effect, and 2) direct target estrogen receptors presented on prostate 
cells (Bonkhoff & Berges, 2009). The role of these steroid hormones in prostate cancer is 
reviewed in the following section. 
Androgens are a group of male sex hormones (e. g. testosterone and 
dihydrotestosterone), which control the differentiation and maturation of male 
reproductive organs, including the prostate gland. Binding of androgens to the androgen 
receptor leads to the expression of target genes (Dehm & Tindall, 2006). Androgens may 
also post-transcriptionally regulate gene expression by modulating the stability of 
mRNAs (Sheflin, Zou, & Spaulding, 2004). Multiple signaling pathways have been 
demonstrated to be critical for prostate cancer initiation and progression (De Marzo, 
DeWeese, Platz, Meeker, Nakayama, Epstein, et al., 2004; Ramsay & Leung, 2009), with 
the androgen signaling pathway being one of the most prominent (Tindall & Tindall, 
2011). 
It has long been proposed that androgens promote prostate carcinogenesis 




supported a link between circulating androgen levels and risk of prostate cancer, although 
the correlation is not conclusive (Isbarn, Pinthus, Marks, Montorsi, Morales, 
Morgentaler, et al., 2009; Morgentaler, 2006). A ‘saturation’ model of androgen action 
on androgen-dependent growth was suggested (Morgentaler & Traish, 2009), which 
states that physiological levels of androgen play an important role in both normal and 
malignant prostate cell proliferation; however, elevated levels of androgens alone do not 
necessarily lead to uncontrolled cell proliferation. Although epidemiologic data suggest 
that androgens alone are not sufficient to promote prostate carcinogenesis (Hsing, 2001), 
abundant biological data make it clear that androgens promote prostate cancer cell 
proliferation. Animal studies also demonstrated that androgens are very strong tumor 
promoters for prostate carcinogenesis. Even low doses of testosterone can induce prostate 
cancer in rodents. When rats are simultaneously treated with estradiol and testosterone, 
prostate cancer incidence is markedly increased, and even a short course of estrogen 
treatment results in a high incidence of prostate cancer (Bosland, 2006). Furthermore, 
ligand-independent activation of androgen receptor (AR) signaling may play a critical 
role in initiation and progression of prostate cancer (Debes & Tindall, 2004; Dehm & 
Tindall, 2006). 
Androgen is known to regulate the alterations and overexpression of the 
TMPRSS2 gene and the ETS transcription factor genes in prostate cancer (Lin, Ferguson, 
White, Wang, Vessella, True, et al., 1999; Tomlins, Rhodes, Perner, Dhanasekaran, 
Mehra, Sun, et al., 2005; Vaarala, Porvari, Kyllonen, Lukkarinen, & Vihko, 2001). 
TMPRSS2 is a membrane-bound serine protease mostly limited to prostate luminal 




Kellokumpu, Kyllonen, & Vihko, 2001), and ETS transcription factors, namely ERG and 
ETV1, are involved in multiple processes, including cell proliferation and cancer cell 
invasion (Hsu, Trojanowska, & Watson, 2004). Current understanding indicates most 
prostate cancers involve a TMPRSS2 ETS translocation and ERG gene overexpression 
(Petrovics, Liu, Shaheduzzaman, Furasato, Sun, Chen, et al., 2005; Soller, Elfving, 
Lundgren, & Panagopols, 2006). Thus, androgen’s induction and promotion of 
expression of ETV1 and ERG are reported to contribute to prostate carcinogenesis.  
Androgens also regulate the expression of both IGF-1 through the androgen 
response elements in the IGF-1 promoter region (Wu, Zhao, Zhao, Pan, Wu, Zhang, et 
al., 2007) and the expression of IGF-1R through a nongenomic event (Pandini, Mineo, 
Frasca, Roberts, Marcelli, Vigneri, et al., 2005). Androgens also modulate the IGF-1 
signaling pathway through regulation of IGF-binding protein expression. Increased levels 
of IGF-1 are known to associate with prostate cancer (Kaaks, Lukanova, & 
Sommersberg, 2000). Increased expression of growth factors and the receptors promotes 
prostate cell proliferation, migration, and tumor angiogenesis, thereby facilitating prostate 
carcinogenesis and cancer progression. 
EGF is another gene that appears to be subject to androgen regulation. Inhibition 
of the EGF receptor can completely suppress androgen-induced proliferation of LNCaP 
cells. Androgens enhance the expression of EGFR, while reduce expression of ERBB2 in 
LNCaP cells (Pignon, Koopmansch, Nolens, Delacroix, Waltregny, & Winkler, 2009). 
Furthermore, ligand dependent or ligand-independent activation of AR promotes 




Vessella, & Tindall, 2008; Libertini, Tepper, Rodriguez, Asmuth, Kung, & Mudryj, 
2007). 
In addition to the regulation of growth factors and respective receptors, androgens 
also affect the downstream effectors, such as PI3K/AKT. The PI3K/AKT pathway is one 
of the most frequently altered signaling pathways in a variety of human cancers and plays 
a critical role in prostate carcinogenesis and its progression (Vivanco & Sawyers, 2002; 
Yuan & Cantley, 2008). Activation of AKT significantly induces the progression of 
prostate cancer (Sarker, Reid, Yap, & de Bono, 2009). Proliferation and survival of 
androgen responsive LNCaP cells depend on the activation of PI3K/AKT, while 
inhibition of AKT or PI3K significantly attenuates androgen-induced cell proliferation 
(Sun, Yang, Feldman, Sun, Bhalla, Jove, et al., 2003). Androgen independent prostate 
cancer cell proliferation is also correlated with increased activity of PI3K/AKT (Murillo, 
Huang, Schmidt, Smith, & Tindall, 2001).  
Estrogens are the primary female sex hormone, however substantial levels of 
estrogens are presented in the male, although markedly less than androgens. Prostate 
growth, differentiation and function are primarily controlled by androgens, but estrogens 
modulate these effects in several ways. Estrogens regulate the development and function 
of prostate throughout stages of a man’s life (Prezioso, Denis, Klocker, Sciarra, Reis, 
Naber, et al., 2007). Estrogens can directly affect prostate through external hormone or 
through estradiol produced by local aromatisation of testosterone (Harkonen & Makela, 
2004). Indirectly, estrogen regulation can interfere with androgen production. 
Upon aging, serum estrogens are known to increase and androgens decrease, 




a possible causal relationship with each other. However, no conclusive clinical evidence 
of a strong correlation between elevated serum estrogen or estrogen/androgen ratio and 
the increased incidence of prostate cancer has been established despite extensive studies 
(Eaton, Reeves, Appleby, & Key, 1999; Gann, Hennekens, Ma, Longcope, & Stampfer, 
1996). However, strong in vitro study evidence shows that excessive or constant exposure 
to estrogens can promote the development of prostatic alterations, disorders and even 
malignancies (Ho, 2004). In previous studies, estrogen was found to stimulate DNA 
synthesis and induce metaplastic epithelial morphology both in human and rat prostate, 
with synergistic effect observed when combined treatment with androgen (Nevalainen, 
Harkonen, Valve, Ping, Nurmi, & Martikainen, 1993; Nevalainen, Valve, Makela, 
Blauer, Tuohimaa, & Harkonen, 1991).  
Estrogen regulation has also been considered as one of the hormonal risk factors 
in association of development of prostate cancer and influences a wide range of genes, 
including IGF (Bosland, 2000; Henderson & Feigelson, 2000; International Prostate 
Health Council Study, 2000). Estrogen also regulate the expression of prostate specific 
genes (Martikainen, Harkonen, Vanhala, Makela, Viljanen, & Suominen, 1987; 
Nevalainen, Valve, Makela, Blauer, Tuohimaa, & Harkonen, 1991). The presence of 
estrogen receptors in the prostate suggests that estrogens may act directly on the prostate. 
In human and rodent prostates, ERβ is the predominant ER subtype, and is expressed in 
the majority of the epithelial cells, with ERα expressed in a limited amount and 
sometimes absent. 
ERα and ERβ are both expressed in prostate epithelium. ERα and ERβ exhibit 




both complementary and antagonistic (Kuiper, Carlsson, Grandien, Enmark, Haggblad, 
Nilsson, et al., 1997). In the human prostate, estrogens mediate epithelial elements 
signaling through ERβ and play a role in repressing cellular proliferation. Absence of the 
ERβ gene leads to the accumulation of cells. ERβ regulates cellular proliferation by 
suppressing estrogen-mediated ERα-signaling pathways that promote AR synthesis 
(Bektic, Berger, Pfeil, Dobler, Bartsch, & Klocker, 2004; Paech, Webb, Kuiper, Nilsson, 
Gustafsson, Kushner, et al., 1997). In this way, 17β-estradiol can trigger distinct effects 
depending on the ratio of ERα and ERβ in the cell. Activation of ERβ also induces cell 
cycle arrest at G2/M phase and cellular apoptosis through p53-independent up-regulation 
of p21 expression and the down-regulation of cyclin B1 (Hedlund, Johannes, & Miller, 
2003). The antiestrogen effect is shown to induce p21 expression and S phase cell cycle 
arrest in Du145 and PC3 prostate cancer cells (Rohlff, Blagosklonny, Kyle, Kesari, Kim, 
Zelner, et al., 1998). In vivo studies indicated that antiestrogens effectively inhibit 
development and progression of experimental and even clinical prostate cancer in a 
transgenic adenocarcinoma of the mouse prostate (TRAMP) model (Gingrich, Barrios, 
Morton, Boyce, DeMayo, Finegold, et al., 1996). 
 
1.1.2.2. Androgen responsive pathway markers 
Association between androgen and risk of prostate cancer makes androgen 
responsive genes ideal to assess the effect of bioactive compounds on androgen-
dependent pathway and androgen-dependent cancer development. 
Prostate-specific antigen (PSA) is a 34 kD, single-chain glycoprotein of 237 




serine protease with chymotrypsin-like, trypsin-like, and esterase-like activities. PSA 
detected in the serum is mainly in the form of a complex with α 1-antichymotrypsin, with 
a minor fraction of free PSA (Malm & Lilja, 1995). PSA mRNA and protein can be up-
regulated by androgen in an androgen receptor-dependent fashion (Payton-Stewart, 
Schoene, Kim, Burow, Cleveland, Boue, et al., 2009). Serum concentrations of PSA 
appear to be correlated with circulating level of androgens and activation of androgen 
receptors. PSA production may be elevated by conditions other than cancer, including 
prostatitis, prostatic intraepithelial neoplasia, acute urinary retention, and renal failure 
(Malm & Lilja, 1995). PSA is particularly sensitive and accurate in the detection of 
residual cancer, recurrent cancer, and cancer progression after treatment, irrespective of 
the treatment modality. PSA can accurately predict cancer status and detect recurrence 
several months before detection by any other method (Oesterling, 1991). PSA is also a 
sensitive and specific immunohistochemical marker for tumors of prostatic origin 
(Goldstein, 2002). Although PSA has been recommended against clinical testing due to 
the risk of over-diagnosis and potential harm (USPSTF, 2012), the use of PSA as an 
indicator in scientific research of prostate cancer is still valid.  
NKX3.1 is a putative prostate tumor suppressor that is expressed in a largely 
prostate-specific and androgen-regulated manner. Human NKX3.1 locates on human 
chromosome 8p21, a region that experiences a high loss of heterozygosity in human 
prostate cancer. Loss of NKX3.1 protein expression is a common finding in human 
prostate carcinomas and prostatic intraepithelial neoplasia (He, Sciavolino, Wing, 
Augustus, Hudson, Meissner, et al., 1997; Vocke, Pozzatti, Bostwick, Florence, Jennings, 




neoplasia, which is the presumed precursor to prostate cancer in humans (Abdulkadir, 
Magee, Peters, Kaleem, Naughton, Humphrey, et al., 2002; Bhatia-Gaur, Donjacour, 
Sciavolino, Kim, Desai, Young, et al., 1999). On the contrary, over-expression of 
NKX3.1 suppresses growth and tumorigenicity of prostate cancer cells in culture (Kim, 
Bhatia-Gaur, Banach-Petrosky, Desai, Wang, Hayward, et al., 2002), which suggested 
NKX3.1 to be a tumor suppressor gene. NKX3.1 expression can be regulated by 
androgens and 17β-estradiol (Korkmaz, Korkmaz, Ragnhildstveit, Kizildag, Pretlow, & 
Saatcioglu, 2000). No expression of NKX3.1 is detected in androgen-independent PC3 
cells, while in androgen-dependent LNCaP cells, NKX3.1 can be upregulated upon 
androgen stimulation (Korkmaz, Korkmaz, Manola, Xi, Risberg, Danielsen, et al., 2004).  
 
1.1.2.3. Role of angiogenesis in prostate cancer 
Angiogenesis is the physiological process of generating new blood vessels from 
pre-existing vessels (Nicholson & Theodorescu, 2004). Tumor formation and growth 
need the support of rich supply of blood, and developing tumors are shown to be able to 
recruit their own blood supply and promote angiogenesis (Fidler, 1995; Gimbrone, 
Cotran, Folkman, & Leapman, 1972). Tumor cells are known to overexpress angiogenic 
factors or alter the regulation of endogenous angiogenic factors to establish an imbalance 
between proangiogenic and antiangiogenic factors in order to induce neovascularization 
(Folkman & Klagsbrun, 1987; Liotta, Steeg, & Stetlerstevenson, 1991). Angiogenesis 
also has important implications in cancer progression to distant sites, since tumor cell 
migration into the circulatory system through surface area of vessels within the tumor 




During angiogenesis, endothelial cells are signaled to switch from a resting state 
to rapid growth (Folkman, Watson, Ingber, & Hanahan, 1989). Tumor cells are known to 
secrete diffusible factors, among which VEGF is the most studied angiogenic growth 
factor (Senger, Perruzzi, Feder, & Dvorak, 1986). Human tumor biopsies exhibit 
enhanced expression of VEGF mRNAs by malignant cells and VEGF receptor mRNAs in 
adjacent endothelial cells, which correlates with microvessel density. On the other hand, 
normal prostate cells express much less VEGF (Ferrer, Miller, Andrawis, Kurtzman, 
Albertsen, Laudone, et al., 1998).  Blockage of VEGF function can completely suppress 
the prostate cancer-induced angiogenesis and cease tumor growth at the pre-vascular 
growth phase (Borgstrom, Bourdon, Hillan, Sriramarao, & Ferrara, 1998).  
 
1.1.2.4. Angiogenesis markers 
Angiogenesis plays a role in tumorigenesis and metastasis. Proteins involved in 
angiogenesis can be used to assess tumor development and effect of bioactive on this 
pathway as a mechanism. 
Vascular endothelial growth factor (VEGF) is a signal protein that stimulates 
vasculogenesis, which is a vital part in promoting angiogenesis in a wide variety of 
normal and neoplastic tissues, and is a potent mitogen for endothelial cells. VEGF's 
normal function is to create new blood vessels during embryonic development, new 
blood vessels after injury, muscle following exercise, and new vessels to bypass blocked 
vessels. When VEGF is overexpressed, it can contribute to disease. Cancers need to 
express VEGF to grow beyond certain size and metastasize (Kollermann & Helpap, 




immunohistochemical studies (Kollermann & Helpap, 2001; Stewart, Panigrahy, Flynn, 
& Folkman, 2001), which is significantly reduced after androgen-deprivation therapy 
(Kwak, Jin, Lee, Park, & Lee, 2002; Latil, Bieche, Pesche, Valeri, Fournier, Cussenot, et 
al., 2000). Blockage of VEGF inhibits androgen-independent prostate cancer growth in 
xenograft models due to the induction of endothelial cell apoptosis (Fox, Higgins, 
Maiese, Drobnjak, Cordon-Cardo, Scher, et al., 2002; Sweeney, Karashima, Kim, Kedar, 
Mian, Huang, et al., 2002), while exogenous VEGF promotes the growth of xenograft 
tumors (Gridley, Andres, & Slater, 1997). Androgen-independent prostate cancer showed 
significantly elevated plasma VEGF concentrations than that of localized prostate cancer, 
and VEGF levels are correlated inversely with survival (George, Halabi, Shepard, 
Vogelzang, Hayes, Small, et al., 2001). Current evidence suggests that cancer cells 
express VEGF for angiogenesis to ensure cancer development, so that circumventing 
oxygen diffusion will no longer be a rate-limiting step in the growth of prostate cancer. 
VEGF expression can be mediated and potentiated by cytokines include TNF (Giraudo, 
Primo, Audero, Gerber, Koolwijk, Soker, et al., 1998), TGF-β (Pertovaara, Kaipainen, 
Mustonen, Orpana, Ferrara, Saksela, et al., 1994), IGF-1 (Warren, Yuan, Matli, Ferrara, 
& Donner, 1996), IL-1β (Li, Perrella, Tsai, Yet, Hsieh, Yoshizumi, et al., 1995), and IL-6 
(Cohen, Nahari, Cerem, Neufeld, & Levi, 1996), as well as others. 
Platelet endothelial cell adhesion molecule (PECAM) is also known as CD31, 
which is a 130-kD protein belonging to the immunoglobulin superfamily. It is expressed 
on platelets, monocytes, neutrophils, certain types of T cells and endothelial cell 
intercellular junctions (Newman, 1997). Engagement of PECAM on the surface of 




Muller, 1995; Reedquist, Ross, Koop, Wolthuis, Zwartkruis, van Kooyk, et al., 2000). 
Functionally, PECAM is shown to play a role in inflammation, angiogenesis and vascular 
development (Privratsky, Newman, & Newman, 2010). PECAM takes effect in the 
adhesion cascade leading to leucocyte–endothelial transmigration during inflammation, 
which serves as a scaffolding molecule in a number of signaling pathways (Ilan & Madri, 
2003). PECAM recruitment and activation will lead to modulation in a number of cellular 
pathways, including the MAP kinase cascades, which play essential roles in a number of 
cell processes by regulating transcription or translation, and AKT activation regulating 
cell survival. Additionally, PECAM has been shown to contain immunoregulatory 
tyrosine-based inhibitory motifs within its cytoplasmic domain. Phosphorylation of these 
residues results particularly in inhibition of tyrosine kinase-mediated signaling, 
proliferation and cellular activation (Newman, 1999). Binding of PECAM and/or soluble 
PECAM inhibits transendothelial migration of leukocytes and angiogenesis, while 
PECAM-deficient mice exhibit abnormalities in their inflammatory and angiogenic 
responses (DeLisser, ChristofidouSolomidou, Strieter, Burdick, Robinson, Wexler, et al., 
1997; Duncan, Andrew, Takimoto, Kaufman, Yoshida, Spellberg, et al., 1999; Solowiej, 
Biswas, Graesser, & Madri, 2003). 
 
1.1.2.5. Role of inflammation in prostate cancer 
Chronic inflammation is a risk factor of several forms of human cancer and ~20% 
of adult cancers are indicated to be related to chronic inflammation (Sfanos & De Marzo, 
2012). Several conditions may contribute to the initiation of prostatic inflammation, 




reflux (De Marzo, Platz, Sutcliffe, Xu, Gronberg, Drake, et al., 2007). Most inflammation 
condition in prostate cancer tissues is chronic, with lymphocytes and macrophages 
involved, however, the factors leading to the chronic inflammation are yet to be identified 
(Sfanos & De Marzo, 2012). 
In prostatic atrophy, inflammatory cell infiltrations are usually observed. It is 
associated with a high frequency to encompass large regions of the prostate, which are 
referred to as proliferative inflammatory atrophy. Atrophic epithelial cells can regenerate 
in response to cellular damage (De Marzo, Marchi, Epstein, & Nelson, 1999). 
Furthermore, genome alterations, which are associated with prostate cancer, are usually 
identified in atrophic lesions (De Marzo, et al., 2007; Nelson, De Marzo, & Isaacs, 2003; 
Putzi & De Marzo, 2000). Previous studies described that 28% instances prostate cancer 
are closely adjacent to areas with chronic inflammation, indicating the merge of these two 
conditions (Wang, Bergh, & Damber, 2009b). 
Some of the hallmark gene expression changes usually found in prostate cancer 
have been observed in proliferative inflammatory atrophy. NKX3.1 and p27 are down-
regulated in prostate atrophy, which is indicative of initiation of prostate cancer (Bethel, 
Faith, Li, Guan, Hicks, Lan, et al., 2006; De Marzo, Marchi, Epstein, & Nelson, 1999). 
p53 expression, together with Ki-67, CK5, COX-2 and GSTP1 expression, also increase 
in areas of acute inflammation (Wang, Bergh, & Damber, 2009a).  
 
1.1.2.6. Inflammation markers 
Cytokines exert cytostatic and immunomodulatory effects on cancer cells, and 




response and angiogenesis (McCarron, Edwards, Evans, Gibbs, Dearnaley, Dowe, et al., 
2002). Cytokines form a highly entangled system linking cancer and inflammation 
(Coussens & Werb, 2002; Maeda & Omata, 2008). The involvement of inflammation in 
prostate cancer discussed in the previous section suggested that the exposure to cytokines 
may be risk factors in both prostate cancer and inflammation.  
TNF-α is strongly expressed in prostate cancer compared with benign prostatic 
tissue, which makes it a strong risk factor for prostate cancer (Chetcuti, Margan, Mann, 
Russell, Handelsman, Rogers, et al., 2001; de Miguel, Royuela, Bethencourt, Santamaria, 
Fraile, & Paniagua, 2000). TNF-α inhibits chemotaxis and proliferation of cancer cell 
lines (Nakajima, Dellipizzi, Mallouh, & Ferreri, 1995; Ritchie, Spangelo, Krzymowski, 
Rossiter, Kurth, & Judd, 1997), induces bcl-2-mediated programmed cell death (Kramer, 
Steiner, Sokol, Handisurya, Klingler, Maier, et al., 2001), activating NF-κB 
(Gunawardena, Murray, Swope, & Meikle, 2002), and inducing cyclooxygenase-2 
expression (Subbarayan, Sabichi, Llansa, Lippman, & Menter, 2001). The effects of 
TNF-α are mediated by TNF-RI and TNF-RII, both of which are expressed by prostate 
cancer cell lines (Nakajima, DelliPizzi, Mallouh, & Ferreri, 1996). TNF-α also plays an 
important role in inflammation by mediating the proliferation and differentiation of 
immune cells, and development of immune response (Miagkov, Kovalenko, Brown, 
Didsbury, Cogswell, Stimpson, et al., 1998). TNF-α is one of the major inflammatory 
mediators secreted by activated macrophage and involved in many crucial events for the 
initiation of both acute and chronic inflammation, such as regulating the production of 
several cytokines, up-regulation of adhesion molecule expression, and activation of 




IL-1β can initiate signal transduction by activation of NF-κB and the MAPKs 
during an inflammatory process (Dinarello, 2004). The activation of NF-κB pathway will 
in turn induce further expression of a series of cytokines, including IL-1β, TNF-α, IL-6, 
and promote an inflammatory process. MCP-1 is a potent chemoattractant for monocytes 
during local immune response and plays an important role in the initiation of 
atherosclerosis. It has been demonstrated that MCP-1 expression is regulated through NF-
κB pathway, and MCP-1 can also be stimulated by TNF-α, IL-1β, and IL-6 (Arefieva, 
Kukhtina, Antonova, & Krasnikova, 2005; Steube, Meyer, & Drexler, 1999).  
 
1.1.2.7. Cancer proliferation markers 
Proliferation is a hallmark of cancer development where cell growth becomes 
uncontrolled. Proliferation marker can be used to assess efficacies of efficacy of prostate 
cancer prevention. 
Proliferating cell nuclear antigen (PCNA) is an auxiliary protein for DNA 
polymerase-α involved in DNA repair, replication, post-replication modifications and 
chromatin assembly, which reaches peak expression during the G1- and G2-phases of the 
cell cycle and can be used as an index of the proliferative activity of cancers. The PCNA 
labeling index is indicated to be lowest in benign epithelium and increases progressively 
in differentiated prostate cancer (Limas & Frizelle, 1994; Nemoto, Kawamura, 
Miyakawa, Uchida, Hattori, Koiso, et al., 1993). Many studies have shown that the 
PCNA index is related to cancer stage (Cher, Chew, Rosenau, & Carroll, 1995; Limas & 
Frizelle, 1994) and a high PCNA labeling index may indicate progression of prostate 




patients with a lower PCNA expression survive significantly longer than those with 
higher ones (Vesalainen, Lipponen, Talja, Alhava, & Syrjanen, 1994). 
The Ki-67 antigen is a nuclear protein that is expressed by non-G0 proliferating 
cells (Cattoretti, Becker, Key, Duchrow, Schluter, Galle, et al., 1992). It was shown that 
Ki-67 labeling indices correlate with cancer, with higher indices indicating more 
progressed cancer stage (Bubendorf, Sauter, Moch, Schmid, Gasser, Jordan, et al., 1996; 
Sadi & Barrack, 1991), which may assist to discriminate between organ-confined and 
metastatic cancer (Cattoretti, et al., 1992; Cher, Chew, Rosenau, & Carroll, 1995; Harper, 
Goddard, Wilson, Matanhelia, Conn, Peeling, et al., 1992). Ki-67 expression is also 
correspond to other factors involved in cancer, such as epidermal growth factor receptor 
(GlynneJones, Goddard, & Harper, 1996), mutant p53 (Thompson, Mellon, Charlton, 
Marsh, Robinson, & Neal, 1992), and chromosomal aberrations (Henke, Kruger, Ayhan, 
Hubner, & Hammerer, 1993).  
 
1.1.3. Link between cholesterol and prostate cancer 
Cholesterol has also been shown to play a role in prostate cancer. It has long been 
reported that cholesterol and other lipids accumulate in solid tumors (White, 1909). The 
association between high circulating cholesterol and increased risk of prostate cancer has 
been reported by a number of cohort studies (Kok, van Roermund, Aben, den Heijer, 
Swinkels, Kampman, et al., 2011; Magura, Blanchard, Hope, Beal, Schwartz, & 
Sahmoun, 2008; Mondul, Clipp, Helzlsouer, & Platz, 2010; Platz, Clinton, & 
Giovannucci, 2008; Shafique, McLoone, Qureshi, Leung, Hart, & Morrison, 2012), 




cancer (Platz, Till, Goodman, Parnes, Figg, Albanes, et al., 2009). The role of cholesterol 
in prostate cancer development has also been demonstrated in animal and cell models 
(Llaverias, Danilo, Wang, Witkiewicz, Daumer, Lisanti, et al., 2010; Xue, Yang, 
Newmark, & Lipkin, 1997), which suggested that cholesterol level may play a role in 
progression and metastasis of prostate cancer (Jacobs, Stevens, Newton, & Gapstur, 
2012; Kok, et al., 2011; Shafique, McLoone, Qureshi, Leung, Hart, & Morrison, 2012). 
Epidemiological studies and pre-clinical models have established hypercholesterolemia’s 
role in the progression of prostate cancer, in which cholesterol functions as a mediator of 
cell proliferation, membrane dynamics, inflammation and steroidogenesis, thus providing 
multiple avenues for this lipid to contribute to prostate cancer progression (Pelton, 
Freeman, & Solomon, 2012). Additionally, the regulation of cholesterol-related pathways 
(such as SREBP-2, HMG-CoA reductase) has been suggested as potential treatment of 
prostate cancer (Freeman & Solomon, 2004; Krycer, Phan, & Brown, 2012). Hence, 
dietary modulation of fat/cholesterol may potentially prevent prostate cancer 
development. 
 
1.1.4. Role of inflammation in prostate cancer 
The relationship between inflammation and cancers is well documented. It can 
trace back to as early as 1863, when Virchow hypothesized that cancers tended to occur 
at sites of chronic inflammation (Balkwill & Mantovani, 2001). Accumulated 
epidemiologic studies support that chronic inflammatory diseases are frequently 
associated with increased risk of cancers (Coussens & Werb, 2002; Philip, Rowley, & 




inflammatory cells (Okada, 2002; Reuter, Gupta, Chaturvedi, & Aggarwal, 2010), 
inflammatory cytokines, chemokines, and enzymes (Coussens & Werb, 2002) all 
contribute to and facilitate cancer development via multiple signaling pathways (Yang, 
Hsieh, Ho, & Lin, 2005).  
The involvement of inflammation in prostate cancer has also caught a great deal 
of attention. Inflammatory cell infiltrations are usually observed, associated with a high 
frequency to encompass large regions of the prostate in proliferative inflammatory 
atrophy. Previous studies described that 28% prostate cancer instances are closely 
adjacent to areas with chronic inflammation, indicating the merge of these two conditions 
(Wang, Bergh, & Damber, 2009b). 
 
1.1.5. The effects of diet on inflammation 
The dramatic changes in dietary composition since the industrial revolution and 
modernized agriculture, and our unchanged physiology, have resulted in a systemic stress 
induced by simply intake of food (Bosma-den Boer, van Wetten, & Pruimboom, 2012). 
The stress will spur inflammatory response and lead to long-term persistent inflammation 
(Kutuk & Basaga, 2003). The western-style diet, in particular, which is high in fat and 
cholesterol, is known to be the leading cause of overweight and obesity (Dausch, 1992). 
Obesity can add up to inflammation, due to the increased expression of cytokines coming 
from the adipocytes (Miranda-Garduno & Reza-Albarran, 2008). Thus, moderation of 





1.1.6. Microbiome in gastrointestinal tract and health 
The word “microbiome” was coined in 2001 to signify "the ecological community 
of commensal, symbiotic, and pathogenic microorganisms that literally share our body 
space" (Lederberg & McCray, 2001). Microbial cells (~1014 cells) outnumber human 
cells by about 10 times, which makes it a very large and complex ecosystem between the 
human body and the residing microorganisms (Hattori & Taylor, 2009; Savage, 1977). 
Recent advances in DNA sequencing technologies have allowed comprehensive 
examination of microbial communities without the need to culture the specific microbes 
in the laboratory.  
Although the exact influence and mechanism remains unknown, previous studies 
have gathered evidence that human microbiome may affect human development, 
physiology, immunity, and nutrition (Dethlefsen, McFall-Ngai, & Relman, 2007). 
Introduction of distal gut microbiota into germ-free animals led to a marked increase in 
adiposity and body fat content within 2 weeks (Backhed, Ding, Wang, Hooper, Koh, 
Nagy, et al., 2004; Turnbaugh, Ley, Mahowald, Magrini, Mardis, & Gordon, 2006). 
Recipients of the microbiota from an obese donor animal had a significantly greater 
increase in adiposity than the ones receiving microbiota from a lean donor, indicating that 
the gut microbiota from obese animals had an increased and transmissible capacity in 
promoting adiposity (Turnbaugh, Ley, Mahowald, Magrini, Mardis, & Gordon, 2006). 
These studies revealed a potential role of the microbiome in the development of obesity 
and other subsequent chronic conditions. 
Considering the overwhelming number and ubiquity of microorganisms, the 




maintenance of health (Hattori & Taylor, 2009). Previous studies have identified 
biomarkers associated with inflammation and functional changes in the intestinal 
microbiome between diseased and healthy human subjects (Karlsson, Tremaroli, 
Nookaew, Bergstrom, Behre, Fagerberg, et al., 2013), and high-fat diet-induced obesity 
in animal models appeared to be associated with changes in the gut microbiome and gut 
inflammation (Albenberg & Wu, 2014; Chen, He, & Huang, 2014). Changes in 
inflammatory status may lead to other chronic conditions in human. 
Long-term and short-term diet patterns can shape the structure and activity of 
human gut microbiome (David, Maurice, Carmody, Gootenberg, Button, Wolfe, et al., 
2014). At early stage of life, breast feeding promotes the colonization of Bifidobacteria 
(up to 90% of flora) in infant, while, formulated milk harbors more diverse microbiome 
in infant, including Bacteroides, Clostridium, and Enterobacteriaceae (Martin & Walker, 
2008; Martin, Jimenez, Heilig, Fernandez, Marin, Zoetendal, et al., 2009). Another study 
showed that, people on a plant-based diet have significantly lower levels of Bacteroides 
spp., Bifidobacterium spp., Escherichia coli, and Enterobacteriaceae spp. than those on an 
animal-based diet (Zimmer, Lange, Frick, Sauer, Zimmermann, Schwiertz, et al., 2012). 
Changes in microbiome can be observed within as short as 24 hours shifting from high-
fat, low-fiber to low-fat, high-fiber diets (Wu, Chen, Hoffmann, Bittinger, Chen, 
Keilbaugh, et al., 2011). Additionally, individual differences in the response of the 
microbial community to dietary change, and in microbial fermentation of dietary 
substrates in the colon needs to be accounted for in the analysis of human microbiome 




between diet and microbiome may be a critical part in studying diet and the influence on 
human health. 
 
1.2. Health benefit of soy 
Soy (Glycine max) plays an important role in the world’s food supply and 
economy. The United States became the world’s leading producer of soy since 1955 and 
has remained so for over half a century (Liu, 1997).  U. S. production of soy in 2011 was 
83 million metric tons, which accounted for more than 30% of world production (FAO, 
2013). Moreover, soy-food sales increased significantly after a 1999 decision by the U. S. 
Food and Drug Administration to allow soy-food labels to display health claim that soy 
protein may reduce risk of heart disease (FDA, 1999). Following sections summarized 
current knowledge on soy’s health promoting effects. 
 
1.2.1. Protection against cardiovascular disease 
Soy’s cardiovascular protective effects in human subjects have been reviewed and 
highlighted in a meta-analysis of 38 controlled clinical trials in an effort to reveal the 
correlation between consumption of soy and lipid levels (Anderson, Johnstone, & 
Cooknewell, 1995). Analysis showed that the average consumption of 47 g soy 
protein/day resulted in significant decreases of total cholesterol (9.3%), LDL cholesterol 
(12.9%) and triglycerides (10.5%). On the other hand, a recent review by the American 
Heart Association Nutrition Committee found a merely 3% decrease in LDL with soy 
protein consumption from 8 randomized trials providing approximately 50 g soy 




Harris, Kris-Etherton, Winston, et al., 2006). The responses appeared to be highly 
dependent on the cholesterol level of the subjects. The meta-analysis performed by 
Anderson and colleagues included earlier studies with strongly hyperlipidemia (total 
cholesterol > 250 mg/dL) patients. It was expected that extreme hyperlipidemia would 
benefit from greater percentage reductions in total and LDL cholesterol, while patients 
with moderate or minor hyperlipidemia were recruited in the later study, which might 
result in the lower efficacy observed. 
Epidemiological studies have long linked soy consumption to a reduced risk for 
cardiovascular disease, and soy protein, soy-derived isoflavones, and sterol were to some 
extent involved in the discussion. (Clerici, Setchell, Pirro, Morelli, Castellani, Giuliano, 
et al., 2004; Sacks, et al., 2006; Sirtori, Galli, Anderson, Sirtori, & Arnoldi, 2009; 
Tripathi & Misra, 2005; Xiao, 2008). A recent review identified soy proteins to be 
partially responsible for the lipid-lowering effects of soy (Sirtori, Galli, Anderson, Sirtori, 
& Arnoldi, 2009). It has also been suggested that isoflavones may act on vascular tissue 
to improve circulation (Ghosh, 2009; Ghosh & Scheepens, 2009; Xiao, 2008). However, 
the active components of soy remain unclear.  
One proposed mechanism of soy’s cardio-protective effects involves the 
inhibition of LDL oxidation and reduction of formation of plaque in the arteries. Soy 
extracts (Astadi, Astuti, Santoso, & Nugraheni, 2009; R. Takahashi, Ohmori, Kiyose, 
Momiyama, Ohsuzu, & Kondo, 2005) and peptides (Rho, Lee, Il Chung, Kim, & Lee, 
2009; Rho, Park, Ahn, Shin, & Lee, 2007) have both been shown to reduce the oxidation 
of LDL cholesterol in vitro or in vivo. It was also reported that the anthocyanins found in 




LDL oxidation (de Pascual-Teresa, Moreno, & Garcia-Viguera, 2010; Kong, Chia, Goh, 
Chia, & Brouillard, 2003; R. Takahashi, Ohmori, Kiyose, Momiyama, Ohsuzu, & Kondo, 
2005). A more recent hypothesis involves the liver’s LDL receptors, which may be 
affected by soy consumption to enhance their uptake of LDL from the serum and 
consequently lower serum LDL levels (Van Horn, McCoin, Kris-Etherton, Burke, 
Carson, Champagne, et al., 2008). 
 
1.2.2. Protection against obesity-related metabolic syndrome 
A more recent trend of soy research involves examining the potential in 
mitigating obesity and related complications (Azadbakht & Esmaillzadeh, 2008; Orgaard 
& Jensen, 2008). The actual efficacy is still under investigation. Mechanistically, the 
estrogen-like activity of soy isoflavones may be playing a role in regulating adipogenesis 
by binding to estrogen receptors, thus decreasing lipoprotein lipase activity, and PPAR 
may also be involved in the regulation (Orgaard & Jensen, 2008).  Levels of genistein, a 
soy isoflavone, ranging from 0.1 to 1.0 μM have been shown to inhibit adipogenesis, 
while higher concentrations (25-50 μM) enhanced adipogenesis, showing a biphasic 
effect (Orgaard & Jensen, 2008). However, evidence in the animal model and in-vitro 
study did not always apply well to human, which made it inconclusive whether 
consumption of soy will benefit obese population. While, many human clinical 
experiments did not show any decrease in body weight as expected, but improvements in 
blood lipids (Orgaard & Jensen, 2008) or improvements in insulin resistance was 





1.2.3. Cancer protective effects of soy 
Soy has also exhibited potential in reducing the risk of certain types of cancer (M. 
Messina, 2006; Nagata, Sonoda, Mori, Miyanaga, Okumura, Goto, et al., 2007; Oba, 
Nagata, Shimizu, Shimizu, Kametani, Takeyama, et al., 2007; Valachovicova, Slivova, & 
Sliva, 2004). Among the cancers investigated, breast and prostate cancers are of 
particular interest due to the sensitivity to sex steroid hormones. 
Epidemiological studies among Asian population had long connected the lower 
breast cancer incident with consumption of soy products, which was usually attributed to 
soy isoflavones (Trock, Hilakivi-Clarke, & Clarke, 2006; Wu, Yu, Tseng, & Pike, 2008). 
Alongside the modest protective effects, concern has also been expressed that the 
estrogenic activity of soy isoflavones may lead to adverse effects on progression and 
recurrence of breast cancer (Magee & Rowland, 2012). On the other hand, there were 
some reviews citing a number of human clinical and epidemiological studies indicating 
no evidence of risk in human (Messina, 2008; Messina & Wu, 2009; Messina & Wood, 
2008). Preventative effect of soy against prostate cancer was also indicated and reviewed 
in previous researches (Messina, 2003), and it is also indicated in clinical trials of the 
therapeutic effect of prostate cancer (Ahmad, Forman, Sarkar, Hillman, Banerjee, 
Doerge, et al., 2008; Banerjee, Li, Wang, & Sarkar, 2008). However, other randomized, 
controlled intervention study did not support that soy consumption can benefit men with 
prostate cancer, while not excluding the possibility of soy’s effect in preventing prostate 
cancer (Bosland, Kato, Melamed, Taneja, Lepor, Torre, et al., 2001). Despite the amount 
of effort from experimental and epidemiological studies, soy products’ effect in breast 




Mechanisms of cancer prevention by soy can be attributed to isoflavones. 
Previous studies suggested that multiple mechanisms of action might be responsible for 
soy’s bioactivity. Isoflavones have been shown to affect the cell cycle, apoptosis, 
differentiation, proliferation, growth, and cell signaling (Banerjee, Li, Wang, & Sarkar, 
2008; Messina, Kucuk, & Lampe, 2006; Zhou, Gugger, Tanaka, Guo, Blackburn, & 
Clinton, 1999). Isoflavones also exhibited antioxidant capacity. They are well-known 
scavengers for reactive oxygen species, but recent research is suggestive of additional 
antioxidant activity beyond direct scavenging of radicals. Genistein in particular has been 
shown to activate transcription factors such as estrogen receptor and stimulate gene 
expression in breast cancer cells (Banerjee, Li, Wang, & Sarkar, 2008). Genistein can 
also inhibit androgen responsive gene expression (Lazarevic, Karlsen, & Saatcioglu, 
2008). These results indicated that the genistein may have broad ability to impact overall 
cellular homeostasis through a variety of mechanisms/pathways. 
 
1.2.4. Protection against other chronic diseases 
Aside from the diseases mentioned above, soy consumption has also been linked 
to the effects in other chronic diseases, though not as extensively studied. Diabetes 
metrics, cognitive function and immune function are among the list of conditions that can 
potentially benefit from consumption of soy or its components (Bhathena & Velasquez, 
2002; Cederroth & Nef, 2009; Lee, Lee, & Sohn, 2005; Ryan-Borchers, Park, Chew, 
McGuire, Fournier, & Beerman, 2006). As with the diseases discussed above, it remains 
unclear whether it is isoflavones, proteins, fiber or some other components causing the 




dissect out the exact active component(s) or compound(s) responsible for any particular 
bioactivity. Compounds may counteract with each other, or show distinct activities 
resulting from different concentration or ratio. Thus, the study of each individual 
component is proven to be necessary and important to gather scientific evidence and 
knowledge to support soy’s health promoting effects. 
 
1.2.5. Bioactive components of soy 
Isoflavones, tocopherols, carotenoids, and phytosterols are the main bioactive 
components in soy (Liu, 1997). Isoflavones are a class of polyphenolics found almost 
exclusively in legumes and most prominently in soybeans. Isoflavones are structurally 
similar to that of estradiol, which bind weakly to estrogen receptors, eliciting weak 
estrogenic responses and earning the title of ‘phytoestrogen’ (Cederroth & Nef, 2009). 
Genistein, daidzein and glycitein are the predominating isoflavones in soy (Fig. 1.3) (Liu, 
1997). Biological activities of soy isoflavones include prevention against atherosclerosis 
and other CVD, obesity, osteoporosis, and cancer (Clair & Anthony, 2005; Gil-Izquierdo, 
Penalvo, Gil, Medina, Horcajada, Lafay, et al., 2012; Orgaard & Jensen, 2008; Sarkar & 
Li, 2003; Taku, Melby, Nishi, Omori, & Kurzer, 2011; Weaver & Cheong, 2005). Due to 
genistein’s estrogenic effect, it was shown that genistein can alter the expression of genes 
involved in estrogen-mediated pathways and induce proliferative response in breast 
cancer cells at 1-5 μM, while higher concentration (25 μM) of genistien can induce 
apoptosis and inhibition of proliferation (Lavigne, Takahashi, Chandramouli, Liu, 
Perkins, Hursting, et al., 2008). It was also reported that genistein and daidzein affect 




Chandramouli, Perkins, Kim, et al., 2006). These findings indicated that the biological 
activities of soy isoflavones are dose-dependent and involved in multiple pathways.  
Tocopherols are members of the Vitamin E family and can act as antioxidants by 
scavenging peroxyl radicals (Britz, Kremer, & Kenworthy, 2008; Liu, 1997). Carotenoids 
also possess antioxidant activity, as their highly conjugated structures are extremely 
vulnerable to oxidation in the presence of light, heat, and oxygen (Lee, Shannon, So, 
Sleper, Nelson, Lee, et al., 2009). Plant sterols are found in soybean oils mostly in the 
non-esterified form. Plant sterols have a base structure very similar to that of human 
cholesterol.  The esterified sterols have been shown to reduce serum cholesterol levels 
when consumed in sufficient quantities (Phillips, Ruggio, Toivo, Swank, & Simpkins, 
2002). 
 
Fig. 1.3. Structure of genistein, daidzein, and glycitein. 
 
 
Other soy phytochemicals have not been studied as extensively. Recently, a novel 
group of phytochemicals, glyceollins, which are also soy phytoalexins, was identified for 
the potential biological activities. The chemical and biological properties of glyceollins 





1.3. Identification, Isolation of soy phytochmicals glyceollins 
Glyceollins are one of the major groups of phytoalexins in soybean. It was first 
reported in elicited soybean by Zahringer et al. in 1977 (Zahringer, Ebel, Kreuzaler, & 
Grisebach, 1977). A good number of studies have been conducted to elucidate the 
biosynthesis of glyceollins in soybean. Banks and Dewick (1983) pointed out that 
phenylalanine, daidzein, 7,2’,4’-trihydroxyisoflavone, 3,9-dihydroxypterocarpan and 
glycinol are precursors for biosynthesis of glyceollin I, II and III (Banks & Dewick, 
1983). In the following decades, plant scientists had shown interest in glyceollins mainly 
for its antifungal and antibacterial effects in soybean (Olah, Schmitthenner, & Walker, 
1982; Parniske, Fischer, Hennecke, & Werner, 1991; Wyss, Boller, & Wiemken, 1991), 
and a number of fungi were identified to be effective elicitors, e.g. Rhizopus oryzae 
(Simmons, Vincken, Roidos, Bovee, van Iersel, Verbruggen, et al., 2011), Mucor 
ramosissimus (Garcez, Martins, Garcez, Marques, Pereira, Oliveira, et al., 2000), 
Diaporthe Meridionalis (Modolo, Cunha, Braga, & Salgado, 2002), Aspergillus sojae 
(Kim, Suh, Kim, Park, Joo, & Kim, 2010). It was determined that, glyceollins are in 
relatively low amount in unstressed soy (1 to 9 µg/g fresh weight of soy, depending on 
the different parts of soy). While, after induction, glyceollins concentration can go up to 
43 to 955 µg/g fresh weight of soy, depending on the different elicitors and parts of soy 
(Boue, Carter, Ehrlich, & Cleveland, 2000; Degousee, Triantaphylides, & Montillet, 
1994; Kraus, Spiteller, Mithofer, & Ebel, 1995). In addition to the effort in isolating 
glyceollins from elicited soy, chemical synthesis was also studied. However, due to the 
time-consuming and multiple steps needed in contiguous ring systems preparation, as 




to date with limited preparation capacity (Khupse & Erhardt, 2008; Khupse, Sarver, 
Trendel, Bearss, Reese, Wiese, et al., 2011; Luniwal, Khupse, Reese, Liu, El-Dakdouki, 
Malik, et al., 2011; Luniwal, Khupse, Reese, Fang, & Erhardt, 2009). 
 
1.4. Biological activities of soy phytochemical glyceollins 
Glyceollins are a group of phytoalexins with antibiotic activity that are 
synthesized in response to infection. Phytoalexins are inducible chemicals involved in 
plants’ self-defense system (Jeandet, Douillt-Breuil, Bessis, Debord, Sbaghi, & Adrian, 
2002), which are low molecular weight, possess anti-microbial activities, and are 
biosynthesized de novo in response to stress, including microbial attack, heavy metal 
salts, or UV radiation (Chamberl.Dw & Paxton, 1968; Murch & Paxton, 1980; Paxton, 
1971). Aside from the anti-microbial activity, some phytoalexins are also indicated to 
exhibit chronic disease prevention and health-promoting effects in human (Boue, 
Cleveland, Carter-Wientjes, Shih, Bhatnagar, McLachlan, et al., 2009).  
Glyceollin I, II, and III (Fig. 2) are the most common isomers isolated from 
soybean (Banks & Dewick, 1983). A number of biological activities were reported by 
previous studies, including antiproliferation (Lee, Kim, Chun, Park, Kim, Kim, et al., 
2010; Payton-Stewart, Khupse, Boue, Elliott, Zimmermann, Skripnikova, et al., 2010; 
Salvo, Boue, Fonseca, Elliott, Corbitt, Collins-Burow, et al., 2006), antiestrogenic 
(Burow, Boue, Collins-Burow, Melnik, Duong, Carter-Wientjes, et al., 2001), 
antibacterial (Weinstein & Albersheim, 1983), antinematode (Huang & Barker, 1991; 
Veech, 1982), antifungal activities (Lee, Kim, Lee, Jeon, Cui, Lee, et al., 2010; 




Kim, Lee, Kim, & Kim, 2010) and attenuation of vascular contraction activity in rat 
(Song, Baek, Jeon, Seo, Kim, Cui, et al., 2010). Hence, accumulating facts suggested that 
glyceollins possess the potential to be a health promoting phytochemical and deserve 
further investigation and characterization. Due to the recentness of discovery of 
glyceollins’ health promoting activities and the limited accessibility of this group of 
compounds, it is noteworthy that most of these reports come from Park and colleagues 
and Boue and colleagues. 
Among the biological activities, glyceollins’ insulinotropic, antiestrogenic, 
antioxidant, anti-inflammation, and antiproliferation effects are of particular relevant to 
this project and are reviewed in the following sections. 
 
 
Fig. 1.4. Structure of glyceollins. 
 
1.4.1. Insulinotropic effect of glyceollins 
Park and colleagues (Park, Ahn, Kim, Lee, Kim, & Kim, 2010; Park, Kim, Kim, 
Kim, & Kim, 2012) performed two studies investigating glyceollins’ role in improving 
glucose homeostasis, they concluded that glyceollins act through regulating glucose 
utilization in adipocytes and modulating β cell function and survival. It was shown that 




accumulation in 3T3-L1 mouse adipocytes. 5 μM glyceollins increased basal glucose 
uptake by 150%. While co-incubation of glyceollins and insulin further stimulated 
maximal glucose uptake above basal levels than that of either stimulus alone. 
Mechanistically, glucose transporter GLUT4 mRNA and protein expression significantly 
increased upon exposure of 5 μM glyceollins for 3 h in 3T3-L1 adipocytes (Boue, 
Isakova, Burow, Cao, Bhatnagar, Sarver, et al., 2012). In addition, glyceollins slightly 
improved glucose-stimulated insulin secretion in Min6 pancreatic β cells, and they 
potentiated insulinotropic actions in dysfunction β cell. This was associated with 
decreased β cell apoptosis because of the attenuation of endoplasmic reticulum stress. 
Glyceollins also potentiated GLP-1 secretion to enhance insulinotropic actions in 
enteroendocrine cells (Park, Ahn, Kim, Lee, Kim, & Kim, 2010). Glyceollins treatment 
reduced blood glucose levels in diabetic mice and prediabetic rats in oral glucose 
tolerance testing. The improvement was associated with increased serum insulin levels, 
hepatic glycogen accumulation and decreased triglyceride storage. It was proposed that 
glyceollins improved glucose homeostasis partly by enhancing hepatic insulin sensitivity 
in type 2 diabetic mice (Boue, et al., 2012; Park, Kim, Kim, Kim, & Kim, 2012). 
 
1.4.2. Antiestrogenic and antiproliferative effect of glyceollins 
Both estrogenic and antiestrogenic activities have been identified in soy 
phytochemicals, Daidzein, the precursor of glyceollins, is known to be weakly estrogenic. 
However, glyceollins have been shown to be antiestrogenic (Burow, et al., 2001; Jiang, 
Payton-Stewart, Elliott, Driver, Rhodes, Zhang, et al., 2010). Mechanistically, glyceollins 




human embryonic kidney cells. It was observed that glyceollins’ antiestrogenic effect on 
ER signaling could lead to a marked suppression of 17β-estradiol-induced proliferation in 
MCF-7 cells (Burow, et al., 2001). Among the three glyceollin isomers, it was shown that 
glyceollin I is the most potent antiestrogenic agent. Glyceollin I could effectively inhibit 
estrogen response element (ERE) transcription and endogenous gene expression in MCF-
7 cells (Payton-Stewart, et al., 2010). 
The antiestrogenic effect was further tested by Zimmermann et al. in athymic 
mice model, and resulted in a 53.4% and 73.1% suppression of MCF-7 and BG-1 tumor 
growth, respectively (Zimmermann, Tilghman, Boue, Salvo, Elliott, Williams, et al., 
2010). Trefoil factor 1 and progesterone receptor were reported to be affected by 
glyceollins treatment, and responsible for their breast cancer protective effect (Wood, 
Clarkson, Appt, Franke, Boue, Burow, et al., 2006).  
Furthermore, glyceollins were also noticed for the effect in suppressing 
tumorigenesis in triple-negative breast carcinoma MDA-MB-231 (ER-, PgR- and 
Her2/neu-) cells. Modest suppression of MDA-MB-231 cell tumor growth in vivo was 
observed upon glyceollins treatment, and a distinct change in microRNA expression 
profiles and proteomes in MDA-MB-231 was identified to be responsible for glyceollins’ 
effect. This study indicated that, aside from antiestrogenic effect, glyceollins could also 
exert antitumor activity in triple-negative breast carcinoma cell systems via alteration of 
microRNA and proteomic expression profiles (Rhodes, Tilghman, Boue, Wang, Khalili, 
Muir, et al., 2012).  
Glyceollins’ antiproliferative effect was also studied in LNCaP human prostate 




inhibition of G1/S progression and correlated with an up-regulation of CDKN1A and 
CDKN1B mRNA and protein levels. Furthermore, glyceollins inhibited LNCaP cell 
growth and cell cycle through a 17-β-estradiol-mediated event instead of an androgen-
mediated event. In addition, glyceollin treatments led to down-regulated mRNA levels 
for androgen responsive genes (Payton-Stewart, et al., 2009). 
 
1.4.3. Antioxidant property of glyceollins 
Soy extract is known for its antioxidant capacity, and a number of phytochemicals 
have been identified, among them genistein and daidzein were the focus of previous 
studies (Slavin, Cheng, Luther, Kenworthy, & Yu, 2009; Slavin, Kenworthy, & Yu, 
2009; Tripathi & Misra, 2005). Structurally, glyceollins (Fig. 2) are similar to genistein 
and daidzein (Fig. 1). Glyceollins have also been reported for their antioxidant activity. 
Kim et.al reported that glyceollins possess potent reducing ability, and can inhibit lipid 
peroxidation, scavenge radicals including singlet oxygen, superoxide anion, 2,2'-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), and 2,2-diphenyl-1-picrylhydrazyl 
(DPPH). In vitro model also indicated glyceollins significantly suppress H2O2-induced 
ROS production in hepa1c1c7 mouse hepatoma cells (Kim, Suh, Kim, Park, Joo, & Kim, 
2010).  
Additionally, glyceollins were shown to induce NADPH:quinone reductase in a 
dose-dependent manner in both Hepa1c1c7 mouse hepatoma and BPRc1 cells. 
Glyceollins also increased the expression of HO1, γ-GCL, and GR by promoting nuclear 
translocation of the Nrf2. Furthermore, glyceollins could upregulate phosphorylation of 




indicated that glyceollins may induce Nrf2-mediated phase 2 enzyme genes through 
activation of the PI3K signaling pathway (Kim, di Luccio, Kong, & Kim, 2011). 
 
1.4.4. Anti-inflammatory effects of glyceollins 
Anti-inflammatory effect of glyceollins was also examined. Glyceollins (0.3 - 3 
μg/mL) was able to inhibit NO production and iNOS, IL-6 and COX-2 gene expression 
induced by lipopolysaccharide (LPS) in RAW264.7 mouse macrophage cells. 
Mechanistically, glyceollins were shown to suppress the LPS-induced phosphorylation of 
NF-κB p65 and regulate NF-κB activity (Kim, Sung, & Kim, 2011).  
 
1.5. Animal models for human diseases 
Due to ethical concern of using human subjects in scientific research, developing 
and characterizing animal models that resemble human metabolism are of great 
importance. Despite the enormous effort and success in human cell model research, only 
part of the need for studying human metabolism can be met, an intact animal is needed 
for many areas of study (Suckling & Jackson, 1993). Especially in nutrition and food 
science area, food is very complex itself with the food content interacting with each 
other, and food-body interaction is well beyond the analysis capability of cell models. 
The use of an animal model makes it possible to investigate both a specific endpoint and 
the big picture of metabolism in a physiological context. 
The major concern of employing laboratory animals is to understand the nature of 




potential alternatives. It will be very hard to seek an animal model that is identical to 
human physiology in every aspect, and researches get increasingly expensive when 
pursuing animal models genetically closely related to human, e.g. monkey or 
chimpanzee, not to mention the ethical concern involved. Even though a compromise has 
to be made, a suitable animal model is key to the success of a scientific research. It is 
important to identify the structures or pathways related to the research question in the 
model animals, and characterize and determine the similarity between animal and human 
counterparts, and also understanding the limitation of the model. 
In the field of dietary components’ effect in cholesterol metabolism and cancer 
prevention, the need for animal models is well established and clearly recognized. Such 
complex systems that involve the digestion and absorption of the food and components, 
transport between different tissues, plus metabolism and effect on cholesterol profile or 
cancer development, cannot be studied in depth without the use of animals. The best 
research strategy is to couple animal models with cell culture systems to gain 
understanding of both the overall influence and the underlying mechanisms at different 
levels.  
Fortunately, the basic pathways and systems of cholesterol metabolism and cancer 
development have been studied for decades and well defined, which makes the search of 
appropriate animal models a targeted endeavor.  
Several types of animal models that are widely used, including a wide range of 
strains of mice, rats, hamsters, rabbits, and other animals. In the following parts, the 





1.5.1. Hamster as model for cholesterol metabolisms 
Since cholesterol has to be transported via lipoproteins, dysregulation of 
cholesterol inevitably leads to fluctuation of lipoprotein levels. Plasma lipoproteins and 
the metabolism are among the most studied attributes in animal models (Suckling & 
Jackson, 1993). Thus, the comparisons between human and animal plasma lipoprotein 
profile and metabolism must be made. However, studies indicated that plasma 
lipoproteins in model animals are significantly different from that of human. In most 
animal species, HDL is the major plasma lipoprotein, whereas in human LDL is the 
dominant lipoprotein, despite wide variations between individuals.  
 
Table 1.1. Plasma lipoprotein profiles in model animals. 
 HDL (mg/dL) VLDL (mg/dL) LDL (mg/dL) 
Human * ~ 40 ~ 60 ~ 100 
Swiss mouse 534 41 69 
Sprague-Dawley rat 240 107 58 
Dog 343 15 26 
African green monkey 447 22 196 
Hamster  46 20 49 
(Chapman, 1986; Quig, Arbeeny, & Zilversmit, 1991) 
* Due to the large discrepancy exist in human lipoprotein levels, data represent desirable 
lipoprotein levels recommended by American Heart Association are used for comparison. 
 
 
Another major difference between human and model animals is the cholesteryl 
ester transfer activity associated with the cholesteryl ester transfer protein (CETP). CETP 
is responsible for promoting the exchange of cholesteryl ester and triglyceride between 
lipoproteins, which results in the net transfer of cholesteryl ester from HDL to LDL in 




(Chapman, 1986; Quig, Arbeeny, & Zilversmit, 1991). Lipoprotein metabolism in rats is 
very different. Rat is especially efficient in clearance of chylomicron and VLDL 
remnants from the circulation, which causes the low LDL levels of the rat. Additionally, 
CETP is absent in the rat (Oschry & Eisenberg, 1982).  
As for cholesterol synthesis, rat shows the highest hepatic cholesterol synthesis 
rate (100%), with squirrel monkey shows about 40% of this rate, the rabbit 20%, human 
about 16% and the guinea pig and hamster even less. Similarly, hepatic ACAT activities 
were shown to be high in the rat and low in the rabbit, human and hamster (Suckling & 
Stange, 1985).  
LDL receptor is the major component in the liver in charge of clearance of plasma 
LDL. LDL receptor activity is controlled and regulated qualitatively by drug or diet, but 
the extent to which varies considerably among species. Hamster can substantial lower its 
hepatic LDL receptor activity in response to dietary saturated fat, which is comparable to 
that in human. While the rat hepatic LDL receptor is much less sensitive (Spady, 
Meddings, & Dietschy, 1986).  
Hamster is widely accepted as a model for lipoprotein metabolism. It has 
cholesteryl ester transfer activity in the plasma and has a significant amount of LDL, 
which is an advantage over other model animals in terms of resemblance to that of human 
(Chapman, 1986; Jiang, Moulin, Quinet, Goldberg, Yacoub, Agellon, et al., 1991; Quig, 
Arbeeny, & Zilversmit, 1991). The synthesis of cholesterol and the regulation of the LDL 
receptor in hamster are sensitive to dietary fat, particularly to saturated fat, in a similar 
way to human (Fernandez, Wilson, Conde, Vergara-Jimenez, & Nicolosi, 1999; Spady, 




in decreased hepatic cholesterol synthesis in hamsters (Daumerie, Woollett, & Dietschy, 
1992; Woollett, Spady, & Dietschy, 1989). Between the two strains of golden Syrian 
hamsters, Charles River Laboratories strain (Wilmington, MA) showed a better response 
to dietary treatment than Bio Breeders strain (Watertown, MA) (Dorfman, Smith, 
Osgood, & Lichtenstein, 2003).  
 
1.5.2. Xenograft model for prostate cancer 
Xenograft model is an established model in prostate cancer research. Xenograft is 
established by injecting established human prostate cancer cells into nude mice, usually 
co-injection with matrigel to increase the success rate (Lim, Liu, Sutkowski, Braun, Lee, 
& Kozlowski, 1993; Pretlow, Delmoro, Dilley, Spadafora, & Pretlow, 1991). More 
recently, fragments of primary cell cultures from prostate carcinomas obtained from 
biopsies, surgery, or intraperitoneal fluid can also be used to initiate xenograft 
(vanWeerden, deRidder, Verdaasdonk, Romijn, vanderKwast, Schroder, et al., 1996; 
Wainstein, He, Robinson, Kung, Schwartz, Giaconia, et al., 1994). The success rate in 
nude mice, which is immunodeficient athymic that lacked T-cell-mediated immunity, was 
slightly lower than that in SCID mice, which lacked both T-cell-mediated and B-cell-
mediated immunity (Lim, Liu, Sutkowski, Braun, Lee, & Kozlowski, 1993; Sato, Gleave, 
Bruchovsky, Rennie, Beraldi, & Sullivan, 1997). However, the absolute absence of 
adaptive immunity always poses a concern in terms of physiological relevance. Xenograft 
models are particularly useful in characterizing the stages of cancer progression, 
including the emergence of androgen-independence, and assessing the efficacy of cancer 




and PC-3 tumor cell xenograft are both well-established xenograft models (Bex, 
Lummen, Rembrink, Otto, Metz, & Rubben, 1999; Gridley, Andres, & Slater, 1997; 
Thalmann, Sikes, Wu, Degeorges, Chang, Ozen, et al., 2000; Tymchuk, Barnard, Heber, 
& Aronson, 2001). Normally, the xenograft can retain the cytogenetic, biologic, and 
molecular features of the original cancer, even after multiple passages. Also, mouse-
derived endothelial cells have been identified between the intravascular space and human 
tumor cells, suggesting contribution of mouse tissues to the vasculature of the tumor 
growth (Lehr, Skelly, Buhler, Anderson, Delisser, & Gown, 1997). Thus, xenograft 
model is suitable for investigating tumor growth, as well as the involvement of 
angiogenesis and other physiological events. 
 
1.6. Real-time polymerase chain reaction 
Polymerase chain reaction (PCR) is a basic molecular biology laboratory 
technique that amplifies a targeted DNA sequence, and real-time polymerase chain 
reaction is a PCR technique that simultaneously amplifies and quantifies the targeted 
DNA. The procedure of real-time PCR follows the general principle of polymerase chain 
reaction. The key feature of real-time PCR is that the amplification of DNA is detected 
and quantified at the end of each thermal cycle, comparing to the standard PCR, in which 
the PCR product is detected at the end of the entire reaction. Common detection methods 
include: (1) non-specific fluorescent dyes that intercalate with any double-stranded DNA, 
such as SYBR Green method, and (2) sequence-specific DNA probes consisting of 




target DNAs, and a fluorescent reporter, which can be detected only after hybridization, 
such as Taqmen method. 
Real-time PCR is mainly used to provide quantitative measurements of gene 
transcription. By quantifying the density of fluorescence which is proportional to the 
concentration of DNA molecules, real-time PCR can be used to determine the genetic 
expression (such as messenger RNA) level of a particular gene changes over time, such 
as in the response of tissue and cell cultures to a phytochemical treatment, progression of 
cell differentiation, or in response to changes in environmental conditions. Real-time 
PCR can also be used to identify the microorganism by targeting species-specific DNA 
sequences and quantify the absolute copy number of target DNAs in the sample. The 
copy number of DNAs can be further calculated to correlate or represent the number of 




The overarching goal of this research is to advance our understanding of potential 
health beneficial effect of soy. Based on existing evidence, we hypothesize that 
components from soy may exert effects on multiple chronic diseases including diet-
induced metabolic syndrome and cancers. We focus on examining the effects of the novel 
soy phytochemicals glyceollins on 1) alleviating metabolic and inflammatory disorders 
resulting from high fat/cholesterol diet and 2) effect on prostate cancer prevention. The 
specific aims for this proposal are: 
 
Specific Aim 1: To test the hypothesis that glyceollins can lower diet induced 
increase in cholesterol levels in plasma and liver. Soy is known to modulate cholesterol 
level and prevent cardiovascular diseases. However, the active component(s) and the 
underlying mechanism remain unclear. Existing literature suggested glyceollins as a 
candidate for soy’s cholesterol-lowering effect. This hypothesis will be tested using a 
hamster model of diet induced metabolic dysregulation. Hamsters fed high-fat diet with 
or without glyceollins supplementation will be assessed for glyceollins’ ability to 
modulate cholesterol and lipid profiles in plasma and liver. Molecular analysis of 
lipid/cholesterol metabolisms will be determined to elucidate mechanisms of action. 
 
Specific Aim 2: To test the hypothesis that glyceollins can prevent prostate 
cancer. Our previous study revealed that glyceollins inhibit androgen responsive LNCaP 
prostate cancer cell growth in culture through inhibition of androgen-dependent 
pathways. The effect of glyceollins in vivo is not known. A prostate cancer cell xenograft 




addressed: 1) whether glyceollins differentially affect androgen-dependent and androgen-
independent cell-derived tumor, and 2) what is the molecular mechanisms of action of 
glyceollins. Marker gene expressions in proliferation, angiogenesis, and androgen 
responsive pathways will be determined to elucidate these questions. 
 
Specific Aim 3: To test the hypothesis that glyceollins supplementation will affect 
gut microbiome composition or population. Human microbiome is a very large and 
complex ecosystem, which has been shown to influence human development and health. 
Recent studies indicated that short and long-term diet can influence the structure and 
activity of the human microbiome.  Glyceollins are a group of phytoalexins, which is 
synthesized by plants to protect against pathogenic attack. In this study, the influence of 
low and high-fat and glyceollins supplemented diet on microbiome in animal models will 
be studied. Certain predominant species of gut bacteria will be selected, and their 
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Hypercholesterolemia is one of the major factors contributing to the risk of 
cardiovascular disease (CVD), which is the leading cause of death in the developed 
countries. Consumption of soy foods has been recognized to lower the risk of CVD, and 
phytochemicals in soy are believed to contribute to the health benefits. Glyceollin is one 
of the candidate phytochemicals synthesized in stressed soy that may account for many 
unique biological activities. In this study, the in vivo cholesterol-lowering effect of 
glyceollins was investigated. Male golden Syrian hamsters were fed diets including 1) 36 
kcal% fat diet, 2) 36 kcal% fat diet containing 250 mg/kg diet glyceollins, or 3) chow for 
28 days. Hepatic cholesterol esters and free cholesterol, hepatic total lipid content, 
plasma lipoproteins, fecal bile acid, fecal total cholesterol, and cholesterol metabolism 
related gene expressions were measured. Glyceollins supplementation led to a significant 
reduction of plasma VLDL, hepatic cholesterol esters and total lipid content. Consistent 




expression of the genes related to cholesterol metabolism in the liver. In contrast, no 
change in plasma LDL and HDL, and fecal bile acid or cholesterol content was observed. 
The cholesterol-lowering effect of glyceollins appeared not to go through the increase of 
bile excretion. These results supported glyceollins’ role as a novel soy-derived 




Hypercholesterolemia is one of the major factors contributing to the onset and 
progression of cardiovascular diseases (CVD), which is the leading cause of death in the 
adult population of industrialized societies (Ortega, Palencia, & Lopez-Sobaler, 2006). It 
is estimated that, by 2020, CVD will continue to be the leading cause and account for 
37% of all deaths (Thomsen, Hansen, Christiansen, Green, & Berger, 2004). Therefore, it 
is imperative to develop preventive strategies against this disease. Besides genetic 
predisposition, increased consumption of high-fat and high cholesterol diets add to the 
risk of CVD (German, Xu, Walzem, Kinsella, Knuckles, Nakamura, et al., 1996; Lecerf 
& de Lorgeril, 2008).  Mechanistically, previous studies have revealed that diet may 
modulate oxidative status and chronic inflammation, which may play a pivotal role in 
atherosclerosis (Hansson, 2009; Kaperonis, Liapis, Kakisis, Dimitroulis, & Papavassiliou, 
2006). Dietary intervention would be an economical and efficient preventive measure. 
Soy is one of the primary agricultural commodities in the United States (Slavin, 
Cheng, Luther, Kenworthy, & Yu, 2009). Soy and soy-derived foods are well-known for 
their health effects and are a rich source of health-promoting bioactive phytochemicals 




lowering effects (Messina & Messina, 2010; Tripathi & Misra, 2005), but the precise 
mechanism and the active components remain unclear (GatchalianYee, Arimura, Ochiai, 
Yamada, & Sugano, 1997; Wilson, Nicolosi, Kotyla, & Fleckinger, 2007). Glyceollins 
(Fig. 2.1), which are synthesized in response to environmental stresses, such as infection, 
are a family of phytoalexins isolated from soy and possess antibiotic activity. Soy 
phytoalexins also include bioactive isoflavones such as genistein and daidzein (Fig. 2.1) 


















Glyceollins have been reported to exhibit antitumor (Lee, et al., 2010; Payton-
Stewart, et al., 2010; Salvo, et al., 2006), antiestrogenic (Burow, et al., 2001), 
antibacterial (Weinstein & Albersheim, 1983), antinematode (Huang & Barker, 1991; 
Veech, 1982), antifungal (Lee, et al., 2010; Lozovaya, Lygin, Zernova, Li, Hartman, & 
Widholm, 2004), antidiabetic (Boue, et al., 2012; Park, Ahn, Kim, Lee, Kim, & Kim, 
2010; Park, Kim, Kim, Kim, & Kim, 2012) and vasodilatory effects in rat (Song, et al., 
2010). Glyceollins were also reported to possess antioxidant and anti-inflammatory effect 
(Kim, di Luccio, Kong, & Kim, 2011; Kim, Suh, Kim, Park, Joo, & Kim, 2010; Kim, 
Sung, & Kim, 2011). The antioxidant and anti-inflammatory properties of glyceollins 
suggest the potential of glyceollins to prevent, delay or treat cardiovascular condition. 
Hence, accumulating evidence suggest that glyceollins have the potential to be health 
promoting phytochemicals and deserve further investigation and characterization. 
Additionally, the contribution of glyceollins to the cholesterol and lipid lowering-effect 
of soy has not been reported. 
The golden Syrian hamster (Mesocricetus auratus) is widely accepted as a suitable 
animal model for studying human cholesterol metabolism (Chapman, 1986; Suckling & 
Jackson, 1993). The lipid profiles and susceptibility to dietary cholesterol of golden 
Syrian hamster is similar to human (Arbeeny, Meyers, Bergquist, & Gregg, 1992; 
KrisEtherton & Dietschy, 1997; Suckling & Jackson, 1993). The current study takes 
advantage of this model to test the hypothesis that glyceollins may exert cholesterol and 
lipid-lowering effect. Hamsters were fed a high-fat diet or a glyceollins supplemented 
high-fat diet. Plasma lipid profiles, liver, fecal lipid contents and microbiome, the 




determined to elucidate the cholesterol-lowering activity of glyceollins and the potential 
mechanisms involved. 
 
2.3. Materials and methods 
Animals and diets. Male golden Syrian hamsters (approximately 80 g, LVG 
strain, Charles River, Wilmington, MA, USA) were given free access to water and rodent 
chow to acclimatize to the environment for 1 week prior to the experiment. For the 
experiment, hamsters were fed a high-fat diet (36 kcal% fat diet), a high-fat diet with 
supplemental glyceollins supplement (36 kcal% fat diet containing 250 mg/kg diet 
glyceollins.), or chow (8728C Teklad Certified Rodent Diet, Harlan Laboratories, Inc, 
Frederick, MD, USA). The experimental diets were formulated and purchased from 
Research Diets, Inc., New Brunswick, NJ, USA. Animals (10 per group) were fed with 
the respective diet for 4 weeks with water available ad libitum. Food intake was recorded 
twice a week and body weights were measured weekly. Diets consisted of 18% protein, 
45% carbohydrate, and 36% fat on a caloric basis supplemented with 0.14% cholesterol. 
Diet compositions are listed in Table 2.1. Glyceollins were given as a mixture of 68% 
glyceollin I, 21% glyceollin II, and 11% glyceollin III. Glyceollins mixture was isolated 
and purified as described previously (Payton-Stewart, et al., 2009; Virgilo A. Salvo, 
Boué, Fonseca, Elliott, Corbitt, Collins-Burow, et al., 2006). The animal use and care 
protocol (Protocol # 10-014) for this study was reviewed and approved by the USDA, 












  gm% kcal% gm% kcal% gm% kcal% 
Protein 21.0 18.0 21.0 18.0 24.3 32.0 
Carbohydrate 52.0 45.0 52.0 45.0 40.2 54.0 
Fat 19.0 36.0 19.0 36.0 4.7 14.0 
Others     23.8  
Total  100.0  100.0  100.0 
kcal/gm 4.58  4.58  3.00  
        
Ingredient gm kcal gm kcal gm kcal 
Casein 222.0 888.0 222.0 888.0   
DL-Methionine 3.0 12.0 3.0 12.0   
Corn Starch 453.0 1812.0 453.0 1812.0   
Maltodextrin 100.0 400.0 100.0 400.0   
Sucrose       
Cellulose 53.0 0.0 53.0 0.0   
Corn Oil 100.0 900.0 100.0 900.0   
Butter 80.0 720.0 80.0 720.0   
Menhaden Oil 20.0 180.0 20.0 180.0   
Mineral Mix 45.0 40.0 45.0 40.0   
Choline 
Bitartrate 
3.0 0.0 3.0 0.0   
Cholesterol 1.5 0.0 1.5 0.0 0.05 0.0 
Glyceollins 0.0 0.0 0.27 0.0 0.0 0.0 
Total 1080.5 4952.0 1080.5 4952.0 1000.0 3000.0 
 
1High-fat and High-fat+Glyceollins diets were formulated and purchased from Research 
Diet (New Brunswick, NJ); 2Chow diet was purchased from Harlan Laboratories 
(Frederick, MD). 
 
Plasma, tissue and fecal sample collection. Hamsters were subject to 12 h 
fasting prior to sacrifice and anesthetized with CO2. Blood was collected by cardiac 
puncture with syringes previously rinsed with potassium EDTA solution (15% w/v), and 
plasma was separated after centrifugation at 1500 rpm for 30 min at 4 °C. Livers and 
adipose tissues were collected, and one part of the tissue immediately frozen in liquid 




purchased from Ambion (Austin, TX, USA) and kept at -80 °C. At the end of the fourth 
week, 48 h fecal samples were collected from the bottom of the cage and kept at -80 °C. 
Plasma lipoprotein analysis. Plasma lipoprotein cholesterol concentrations were 
determined by size exclusion chromatography as previously described (German, et al., 
1996). Briefly, an Agilent 1100 chromatograph was employed with a postcolumn 
derivatization reactor, consisting of a mixing coil (1615-50 Bodman, Aston, PA, USA) in 
a temperature-controlled water jacket (Aura Industrials, Staten, NY, USA). A Hewlett-
Packard (Agilent, Palo Alto, CA, USA) HPLC pump 79851-A was used to deliver 
cholesterol reagent (Roche Diagnostics, Indianapolis, IN, USA) at a flow rate of 0.2 
mL/min. Bovine cholesterol lipoprotein standards (Sigma Aldrich, St. Louis, MO, USA) 
were used to calibrate the signal on the basis of peak areas. 15 µL of plasma was injected 
via an Agilent 1100 auto sampler onto a Superose 6HR HPLC column (Pharmacia LKB 
Biotechnology, Piscataway, NJ, USA). The lipoproteins were eluted with a pH 7.0 buffer 
solution containing 0.15 M sodium chloride and 0.02% sodium azide at a flow rate of 0.5 
mL/min. Plasma lipoprotein concentration was calculated based on a standard curve. 
Liquid chromatography-mass spectrometry analysis of plasma concentration 
of glyceollins. LC-ESI-MS and LC-ESI-MS/MS analyses were conducted on an Agilent 
1100 series LC system (Agilent, Santa Clara, CA) coupled to a TSQ Vantage™ Triple 
Quadrupole Mass Spectrometer (Thermo Scientific, Middletown, VA). Separation was 
performed on an Agilent Eclipse XDB C18 column (4.6 × 150 mm ID, 5 μm). Ten 
microliters was injected onto the column held at 25 °C. The binary mobile phase 
consisted of mobile phase A (water with 0.1% formic acid) and mobile phase B 




at 2% A for 10 min; 14-16 min 2% A to 30% A and hold at 30% A for 7 min; the flow 
rate was 0.200 mL/min. The UV absorbance detector was set at 285 nm. For positive ion 
LC-ESI-MS and LC-ESI-MS/MS analyses, electrospray parameters were set at the 
following: sheath gas pressure of 60 psi, ionspray voltage of 3500 V, auxiliary gas 
pressure of 15 psi, collision gas pressure of 1.5 mTorr, capillary temperature of 268 °C. 
Declustering potential and collision energy were maintained at -12 V and 16 eV, 
respectively. Parent and product mass scan were performed at 339.000 and 229.042.  
Hepatic lipid extraction. Livers were excised and immediately frozen in liquid 
nitrogen, and then stored at –80 ºC prior to analysis. The extraction method was modified 
from Folch method (Ametaj, Bobe, Lu, Young, & Beitz, 2003; Folch, Lees, & Sloane 
Stanley, 1957). Approximately 0.15 g of frozen liver was minced and transferred into a 
test tube. 6 mL of chloroform/methanol (2:1, v/v) was then added, followed by a 2 min 
homogenization and 30 s of sonication at 30% power level. Samples were then incubated 
with shaking for 2 h on a platform shaker. After incubation, 2 mL of double distilled 
water was added. Samples were then centrifuged for 20 min at 500 g. After 
centrifugation, the bottom layer was carefully aspirated into a new test tube and incubated 
overnight. It was then filtered through a 0.22 µm filter and dried by stream of nitrogen. 
The dried lipid was weighed and redissolved in isopropanol with 10% Triton X-100 and 
used for triglyceride and cholesterol analysis as described below.  
Triglyceride, total cholesterol and free cholesterol in the liver. Hepatic 
triglyceride, total cholesterol and free cholesterol were enzymatically determined using 




Cholesterol E and Free Cholesterol E, Wako Chemicals, Richmond, VA, USA) following 
manufacturer’s protocols.  
Fecal bile acids and cholesterol extraction. Fecal bile acids and cholesterol 
were extracted using a modified protocol (Allen, Bristow, & Yu, 2004). Fecal samples 
were collected during 48 h period on days 26-28 after initiation of the experiment. The 
samples were lyophilized, pulverized using pestle and mortar, and weighed. A dried fecal 
sample (0.10 g) was hydrolyzed in 1.0 mL of 2 M KOH at 50 °C for 5 h. The cooled 
mixture was then extracted with two 6-mL portions of diethyl ether to remove 
nonsaponifiable components. Subsequently, 1 mL of 20% sodium chloride followed by 
0.2 mL of 12 M hydrochloric acid was added to the remaining mixture. The acidified 
mixture was extracted with two 6-mL portions of diethyl ether, and the pooled ether 
extracts were evaporated by nitrogen and redissolved in 0.5 mL of ethanol. The samples 
were used for fecal bile acid and cholesterol determination as follows. 
Fecal bile acids and cholesterol analysis. Fecal bile acid content was 
enzymatically determined by 3α-hydroxysteroid dehydrogenase (3α-HSD) (Liu, Wang, 
Yao, Gao, & Yu, 2010). β-nicotinamide adenine dinucleotide hydrate (NAD), nitroblue 
tetrazolium chloride (NBT), diaphorase, 3α-HSD, and cholic acid were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). NAD, NBT, diaphorase, and 3α-HSD were 
prepared in 0.01 M phosphate buffer at pH 7.0. The reaction mixture included 40 μL of 
sample or standard with 4 µL of Triton X-100, 50 µL of NAD (2.5 mM), 50 µL of NBT 
(0.61 mM), 50 µL of diaphorase (625 U/L), 50 µL of 3α-HSD (625 U/L). The mixture 
was incubated for 60 min at ambient temperature, after which 40 µL of phosphoric acid 




measured at 530 nm. Cholic acid in ethanol was used to generate a standard curve, and 
the amount of fecal bile acid obtained was determined using the standard curve. 
Cholesterol was determined by the same assay as for liver described above.  
Total RNA isolation, cDNA synthesis and gene expression analysis from liver 
and adipose tissue. To determine the gene expression changes, liver and adipose 
preserved in RNALater were cut into 0.1 to 0.2 g pieces and homogenized using a 
Precellys 24 (Bertin Technologies, Villeurbanne, France). RNeasy Mini Kit and RNeasy 
Lipid Tissue Mini Kit (Qiagen, Valencia, CA, USA) were used for total RNA isolation 
for liver and adipose, respectively. StrataScript First Strand complementary DNA 
Synthesis kit from Stratagene (Santa Clara, CA, USA) was used to reverse transcribe 
complementary DNA. Real-time PCR was performed on an Applied Biosystems 7900HT 
Sequence Detection System using Fast SYBR Green Master Mix by Applied Biosystems 
(Carlsbad, CA, USA). Primers used in this study are listed in Table 2.2. Relative mRNA 
expression levels were calculated using the delta Ct method (J. S. Yuan, Reed, Chen, & 
Stewart, 2006). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was 






Table 2.2. Sequences of Real-time PCR primers 
Genes Direction Sequence (5’-3’) 




















































TaqMan primers  
GAPDH 
Forward GAACATCATCCCTGCATCCA  
Reverse CCAGTGAGCTTCCCGTTCA  
Probe CTTGCCCACAGCCTTGGCAGC 
LPL 
Forward TTTAACTACCCCCTGGACAATGTC  





Statistical analysis. All end point assays for each sample were conducted in 
triplicate, and the average was used for group analysis, data for each treatment group 
were presented as mean ± standard error. Significance level of differences in means was 
detected using one-way ANOVA and Tukey’s test. Statistics analysis was performed 
using IBM SPSS Statistics 19.0 (2010, IBM Corporation, Armonk, NY, USA) or 
Graphpad Prism 6 (2012, Graphpad Software, La Jolla, CA, USA). Statistical 
significance was defined at p ≤ 0.05.  
 
2.4. Results 
Body Weight and Food Intake. There was no difference in body weight or body 
weight gain between any of the diet treatments during the experimental period (Table 
2.3). Food intake was significantly higher in the group fed with chow diet, but caloric 
intake was higher in the high-fat diet, and high-fat diet supplemented with glyceollins 
groups due to their higher fat content (Table 2.3).  
 
Table 2.3. Effect of different diets on body weight and food intake 
 High-fat Glyceollins Chow 
body weight (g) 95.83 ± 5.30a 95.91 ± 4.04a 96.87 ± 3.94a 
body weight gain (g) 17.48 ± 4.98a 18.95 ± 6.54a 20.83 ± 3.97a 
food intake (g/day) 5.82 ± 0.43a 5.89 ± 0.60a 7.59 ± 0.31b 
calorie intake (kcal/day) 26.67 ± 1.97b 26.97 ± 2.76b 22.76 ± 0.93a 
Body weight and food intake was presented as mean ± SEM (n = 10). Significance level 
of differences in means was detected using one-way ANOVA and Tukey’s test. Numbers 
marked with different letter are significantly different from each other at p ≤ 0.05. 
 
 
Plasma Lipoprotein Cholesterol Content. Compared to the chow diet, 




(VLDL) (366%), low-density lipoprotein (LDL) (482%), and total lipoprotein levels 
(51%) in hamster plasma (Fig. 2.2). Animals on high-fat diet supplemented with 
glyceollins showed significantly lower (30% less) VLDL than animals on the high-fat 
diet. We also found a trend in reduction of LDL by 19% and total lipoprotein level by 9% 
in the animals fed with glyceollins, however reductions in LDL and total lipoprotein level 
did not reach statistical significance (Fig. 2.2). There was no difference in high-density 




Fig. 2.2. Effects of glyceollins supplement on plasma lipoprotein cholesterol level. 
Hamster plasma from different diet groups was harvested and Plasma lipoprotein 
cholesterol concentrations were determined by size exclusion chromatography as 
A. VLDL

























































described in Material and Methods. A) Very Low-Density Lipoprotein (VLDL), B) Low-
Density Lipoprotein (LDL), C) High-Density Lipoprotein (HDL), and D) Total 
Lipoprotein. Each column represents the mean ± SEM (n = 10). Columns marked with 
different letters are significantly different from each other at p ≤ 0.05. 
 
 
Cholesterol and Lipid Content of Liver. In animals fed the high-fat diet, hepatic 
cholesterol esters and free cholesterol increased 759% and 27%, respectively, compared 
to that of animals on the chow diet, and cumulatively resulted in 266% increase in total 
cholesterol (Fig. 2.3). Glyceollins supplementation in the high-fat diet reduced hepatic 
cholesterol esters and free cholesterol by 20% and 14% (Fig. 2.3B, 2.3C). Overall, the 
total lipid content in liver of high-fat diet animals was 82% higher than those on chow 
diet (Fig. 2.3E). Total lipid in the liver of glyceollins supplemented animals were 18% 
lower than high-fat diet fed animals. There were no differences in hepatic triglyceride 
level between the animals from different diet groups (Fig. 2.3D). Consistent with lower 
lipid level in glyceollins treated animals, we also observed that the livers of the 
glyceollins fed animals appeared dark red, smooth and more similar to that of chow fed 






Fig. 2.3. Effects of glyceollins on hepatic triglyceride and cholesterol level. Livers were 
harvested from animals on different diets and hepatic lipid extracted and enzymatically 
determined as described in Materials and Methods. A) Hepatic Total Cholesterol, B) 
Hepatic Cholesterol esters, C) Hepatic Free Cholesterol, D) Hepatic Triglycerides, and E) 
Hepatic Total Lipid Content. Each column represents the mean ± SEM (n = 10). Columns 
marked with different letters are significantly different from each other at p ≤ 0.05. 
 
 
Bile Acid and Cholesterol Content of Feces. There was no significant difference 
between the diet groups for fecal bile acid content (Fig. 2.4). Compared to animals on the 
chow diet, higher fecal total cholesterol (170%) levels were detected in high-fat diet fed 
animals, but there was no difference between animals fed with or without glyceollins. 
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Fig. 2.4. Effects of glyceollins on fecal bile acid and cholesterol level. Two-day fecal 
samples were collected for animals on different diets and fecal bile acid and total 
cholesterol was extracted and determined as described in Materials and Methods. A) 
Fecal Bile Acid, and B) Fecal Total Cholesterol. CA equiv stands for cholic acid 
equivalents. Each column represents the mean ± SEM (n = 10). Columns marked with 
different letters are significantly different from each other at p ≤ 0.05. 
 
 
Relative Expression of Genes Related to Cholesterol and Bile Acid 
Metabolism. Expression of hepatic genes related to cholesterol, bile acid, and fatty acid 
metabolism were determined to elucidate potential mechanisms of action. There was no 
difference in the expression of the mRNA levels of LDL receptor, which binds to LDL 
particles in circulation, between animals fed with different diets (Fig. 2.5A). Compared to 
the chow diet, the high-fat diet significantly decreased the hepatic mRNA level of the 
HMG-CoA reductase (32%) (Fig. 2.5B), which is the rate-limiting enzyme of the 
mevalonate pathway involved in cholesterol synthesis. Animals fed the glyceollins 
supplemented diet showed a similar decrease in hepatic HMG-CoA reductase as animals 
fed the high-fat diet. Another rate limiting enzyme in cholesterol synthesis, CYP51, 
which converts lanosterol to cholesterol, was down-regulated ~80% in high-fat diets with 
or without glyceollins supplemented as compared to chow diet (Fig. 2.5C). Liver X 
receptor (LXR) α and peroxisome proliferator activated receptor (PPAR) α, transcription 
A. Fecal bile acid
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factors regulating fatty acid β-oxidation, did not exhibit differences between the diets 
(Figs. 2.5D, 2.5E).  
 
Fig. 2.5. Effects of glyceollins on liver LDL receptors, cholesterol synthesizing enzymes, 
and cholesterol metabolizing transcription factors mRNA levels. Livers were harvested 
from animals on different diets, total mRNA extracted and mRNA level determined using 
Real Time PCR as described in Materials and Methods A) liver LDL receptor, B) 
HMGCoAR, C) CYP51, D) LXRα and E) PPARα gene. Results express as relative 
expression levels (mean ± SEM, n = 10) to chow diet. Columns marked with different 
letters are significantly different from each other at p ≤ 0.05. 
 
 
ABCG5 and ABCG8 function as half-transporters to limit intestinal absorption 
and promote biliary excretion of sterols. High-fat diet significantly elevated both ABCG5 
and ABCG8 mRNA expression by 309% and 128%, respectively (Figs. 2.6A, 2.6B). 
Animals fed glyceollins supplemented diet expressed significantly lower levels of 
ABCG5 (29%), and ABCG8 (25%) mRNA as compared to the high-fat diet (Figs. 2.6A, 
2.6B). CYP7A1 encoding the enzyme for the initial rate-limiting step of bile acid 
synthesis, was increased by 63% in glyceollins supplemented diet, though did not reach 
A. LDLR































































































































statistical significance (Fig. 2.6C), while high-fat diet and chow diet exhibited similar 
expression level of CYP7A1.  
 
 
Fig. 2.6. Effects of glyceollins on liver cholesterol transporting and catabolizing enzymes 
mRNA levels. Livers were harvested from animals on different diets, total mRNA 
extracted and mRNA level determined using Real Time PCR as described in Materials 
and Methods A) ABCG5, B) ABCG8, and C) CYP7A1. Results were expressed as 
relative expression levels (mean ± SEM, n = 10) to chow diet. Columns marked with 
different letters are significantly different from each other at p ≤ 0.05. 
 
 
The mRNA levels of fatty acid synthase (FAS) and acyl-CoA oxidase (ACOX), 
genes encoding the rate-limiting enzymes in peroxisomal β-oxidation, were not affected 
by the different diets (Figs. 2.7A, 2.7B). Sterol Regulatory Element-Binding Protein 
(SREBP)-1c is a transcription factor that binds to the sterol regulatory element DNA 
A. ABCG5








































































sequence upstream of genes for fatty acid biosynthesis. Animals on the high-fat diet, with 
or without glyceollin, had higher hepatic SREBP-1c expression (~170%) than animals on 
chow diet (Fig. 2.7C). 
The LPL gene encodes lipoprotein lipase, which has the dual functions of 
triglyceride hydrolase and ligand bridging factor for receptor-mediated lipoprotein 
uptake. In this study, LPL expression level in liver was elevated in the high-fat diet by 
158%, while glyceollins supplementation reduced liver LPL by 27% (Fig. 2.7D). On the 
other hand, adipose LPL mRNA levels were significantly lower (35%) in animals that 
consumed glyceollins as compared to animals on the high-fat or chow diets (Fig. 2.7E). 
Fig. 2.7. Effects of glyceollins on lipid metabolizing genes in liver and adipose tissue. 
Livers and adipose tissues were harvested from animals on different diets, total mRNA 
extracted and mRNA level determined using Real Time PCR as described in Materials 
and Methods. A) FA synthase, B) ACOX, C) SREBP, D) Liver LPL, and E) Adipose 
LPL. Results were expressed as relative expression levels (mean ± SEM, n = 10) to chow 





























































































































Glyceollins Reduced Inflammation Cytokine Expressions in the Liver. In 
liver, we observed inhibition of high-fat diet induced increase in IL-6 and TGF-β in the 
animals supplemented with glyceollins (Fig. 2.8). TGF-β in particular, as described 
above, is an important regulator of hepatic stellate cells and liver fibrosis (20). These 
results thus support an anti-inflammatory effect of glyceollin in liver. In our short term 
feeding model, although changes in cholesterol/lipid occurred, we did not observe 
differences in inflammatory markers, such as IL-1β, IL-6, or IFNγ, within the diet groups 
in the adipose tissue. These results suggest longer feed period may be necessary to 
observe an effect by glyceollins on inflammation parameter in adipose.  
 
Fig. 2.8. Effects of glyceollins on inflammatory cytokine genes in liver. Livers were 
harvested from animals on different diets, total mRNA extracted and mRNA level 
determined using Real Time PCR as described in Materials and Methods. A) IL-1β, B) 
IL-6, C) TNF-α, D) TGF-β, and E) IFNγ. Results were expressed as relative expression 
levels (mean ± SEM, n = 10) to chow diet. Columns marked with different letters are 



































































































































Fecal Microbiome in Hamster. In the 4-week feeding study in hamster model, 
Bifidobacteria was significantly reduced by high-fat diet (87% comparing to chow diet 
group) and a significant increase in Lactobacillus (140%) was observed (Fig. 2.9A). 
High-fat diet also induced Ruminococcus (940%), Bacteroidetes (814%), and Firmicutes 
(1021%) comparing to chow diet group, however, due to the huge individual differences 
within and across groups, none of these changes achieved statistical significance (Fig. 
2.1A). In animals fed high-fat diet supplemented with glyceollins, a trend of increase was 
observed in Akkermansia, Ruminococcus, Bacteroidetes, and Firmicutes, however, no 







Fig. 2.9. Fecal microbiome in hamsters consuming high-fat, high-fat supplemented with 
glyceollins, or chow diet. Comparisons were made between chow and high-fat groups 
(A), and high-fat and high-fat supplemented with glyceollins (B), and presented as 
percent change. Statistical significance was defined at p ≤ 0.05 and marked with asterisk. 
 
 
Plasma Concentration of Glyceollins. In animals fed high-fat and chow diets, 
glyceollins were undetected in plasma by mass spectrometry. Average concentration of 
glyceollins was determined to be 0.14 ± 0.025 μM in supplemented animals, ranging 
from 0.05 to 0.32 μM. Daily consumption of glyceollins in the diet was calculated to be 

























































has a blood volume of 78 mL/kg (Drexelmed.edu). Thus, about 19% of ingested 






























































































































































2.5. Discussion  
Glyceollins are a family of major phytoalexins and phytoestrogens in stressed soy 
(Boue, Burow, Shih, Carter-Wientjes, & Cleveland, 2004; Kim, Lim, Kim, & Kim, 2012) 
(Fig. 2.1). We have previously shown that a soy protein diet enriched with isoflavones 
and glyceollins reduced cholesterol in postmenopausal female Cynomolgus monkeys 
(Wood, Boue, Collins-Burow, Rhodes, Register, Cline, et al., 2012), which suggested that 
glyceollin might be responsible for the effects in cholesterol reduction. This study 
assessed the short term (4 weeks) effect of glyceollins supplementation on lowering 
cholesterol level in animals fed with a high-fat western style diet. As shown in Fig. 2.2A, 
glyceollins significantly reduced the plasma concentration of VLDL by 30% in hamsters 
fed on high-fat diet. VLDL is responsible for transporting endogenous triglycerides, 
phospholipids, cholesterol, and cholesterol esters. Elevated VLDL is a critical factor in 
the onset and progression of cardiovascular conditions (Nielsen & Karpe, 2012; Shelness 
& Sellers, 2001). The higher circulating level of VLDL in animals consuming a high-fat 
diet is reflective of increased lipid and cholesterol intake. Our results suggested 
glyceollins supplementation, by reducing high-fat diet induced increase of VLDL, may 
be useful to prevent potential detrimental effects of high-fat intake. The plasma 
concentrations of LDL and total lipoprotein were also slightly lowered by 19% and 9% 
upon glyceollins supplementation (Figs. 2.2B, 2.2D), while HDL level was unaffected 
(Fig. 2.2C).  
The consumption of the high-fat diet induced an increase of hepatic cholesterol 
esters and free cholesterol compared to the chow diet (Fig. 2.3). However, glyceollins 




total lipid content. These effects of glyceollins suggest less cholesterol resided in liver, 
and less is available for packaging into VLDL, therefore leading to lower circulating 
VLDL level. Additionally, livers from glyceollins fed animals were dark red and smooth, 
were similar to chow fed animals. The high-fat diet animals’ livers, on the other hand, 
were pale and mottled, which was suggestive of lipid accumulation. These results 
supported our previous conclusion suggesting that glyceollins supplementation may 
contribute to the reduction of cholesterol level in plasma (Wood, et al., 2012). 
Typical dietary cholesterol reducing agents, such as cholestyramine, increase 
fecal bile acid excretion (Suckling, Benson, Bond, Gee, Glen, Haynes, et al., 1991). 
However, fecal excretion of bile acid and cholesterol appeared not to be responsible for 
glyceollins’ effect on VLDL, and no change in these parameters was observed in this 
study (Fig. 2.4). 
To further elucidate the mechanism of glyceollins action, we also examined the 
expression of genes involves in lipid metabolism. Our results indicated the changes in 
gene expression due to feeding glyceollins were limited but also appeared reflective of 
glyceollins effect on liver lipid and cholesterol contents. Since the LDL receptor 
functions to bind and internalize circulating LDL-cholesterol, and liver removes ~70% 
LDL from the circulation through LDL receptors, it can be a source of increased hepatic 
cholesterol. In this study, liver LDL receptor gene expression did not appear to change 
significantly regardless of the type of diet (Fig. 2.5A). ABCG5 and ABCG8, two 
transporters for cholesterol excretion, were significantly up-regulated by high-fat diet as 
compared to chow. However, expressions of both genes in animals fed with glyceollins 




LPL, a dual function enzyme involved in cholesterol/lipid transport, was significantly up-
regulated in high-fat diet fed animals compared to chow fed animals. The glyceollins 
supplemented diet significantly lowered hepatic LPL expression compared to the animals 
fed high-fat only diet. The changes in ABCG5, 8 and LPL appeared to be reflective of 
hepatic lipid/cholesterol status in glyceollins fed animals. We did observe a trend of bile 
synthetic enzyme CYP7A1 up regulation and increased bile acid excretion in glyceollins 
fed animals compared to high-fat only animals. However, there was a large difference 
between animal in these parameters and was not statistically significant. It is possible that 
a longer feeding period or increase in animal number might confirm this observation and 
warrant further study. One unique observation in our study was glyceollins fed animals 
appeared to have significantly lower adipose LPL mRNA level than high-fat or chow fed 
animals. This result suggested that glyceollins might have an effect on adipose tissues, 
such as prevent accumulation of lipid in adipose tissues. Since our study was designed to 
investigate short term effects and no body weight or adipose weight changes were 
observed, further long term studies would be necessary to elucidate the biological 
significance and mechanisms of glyceollins’ effect on adipose LPL.  
Consumption of a high-fat, high cholesterol diet can lead to gene changes that 
would compensate for changes in dietary intake. In our current hamster study, as 
expected, significant down regulation of cholesterol synthesis related gene HMG-CoA 
reductase and CYP51 (Fig. 2.5B, 2.5C) were observed in hamsters on the high-fat diets 
compared to the control group. This is consistent with the fact that abundant cholesterol 
is available to cells upon consumption of high-fat diet, de novo synthesis of cholesterol 




cholesterol synthesis, no effect was observed in this study, which suggested a lack of 
glyceollins influence on this cholesterol synthesis pathway both in a hamster model. 
Similar results were also observed for SREBP-1c, however in this case the high-fat diet 
lead to significant up-regulation of this gene as compared to the chow fed animals. 
Glyceollins did not affect SREBP-1c expression when compared to high-fat diet animals. 
Our results indicated that several pathways appeared not to be affected by dietary 
perturbation at the transcriptional level. We did not observe significant differences in 
LXRα, PPARα, FAS or ACOX mRNA expression between the different diets. None of 
these pathways were affected by glyceollins supplementation. These data would support 
the notion that, under our experimental condition and bioavailability of glyceollins in 
hamster, cholesterol synthesis and excretion were the main pathways animals used to 
adapt to the high-fat diet.  
In this study, high-fat diet and glyceollins’ effect on microbiome was also 
investigated. High-fat inhibited Bifidobacteria and induced Lactobacillus in the fecal 
microbiome (Fig. 2.9A). Bifidobacteria and Lactobacillus are known to be involved in 
energy metabolism in gut microbiome (Cani & Delzenne, 2009; Ley, Backhed, 
Turnbaugh, Lozupone, Knight, & Gordon, 2005), previous studies have also reported diet 
conversion high in fat content can alter population of Bifidobacteria and Lactobacillus 
(Brinkworth, Noakes, Clifton, & Bird, 2009; Zeng, Liu, Jackson, Yan, & Combs, 2013). 
However, there were other reports indicating opposite changes induced by high-fat diet in 
these microorganisms (Cani, Bibiloni, Knauf, Neyrinck, Delzenne, & Burcelin, 2008; 




microbiome may be highly dependent on animal models, diet compositions, and also 
fecal collection methods. 
For the first time, our study gathered direct evidence that glyceollins 
supplementation in a high-fat diet significantly reduced VLDL, hepatic cholesterol esters, 
hepatic free cholesterol and hepatic total lipids, as well as hepatic inflammatory cytokines 
in animals. The effects of glyceollins on hepatic lipid and cholesterol levels appeared to 
contribute to molecular changes in hepatic ABCG5, 8 and LPLs mRNA levels. However, 
the actual molecular mechanism of cholesterol-lowering effect of glyceollins in-vivo 
remains unclear and needs further investigation. Given that glyceollins are naturally-
derived phytochemicals in stressed soy, our results suggested that the inclusion of 
glyceollins in diet may benefits the population by lowering VLDL cholesterol and 
decreasing the risk for cardiovascular disease. 




Chapter 3: Prostate cancer preventative effect of glyceollins in 
xenograft mouse model 
 
3.1. Abstract 
Glyceollins are soy-derived phytoalexins that have been proposed to be candidate 
cancer preventive compounds. Prostate cancer is identified as the most prevalent cancer 
in U.S. population. Previous research has shown that the glyceollins significantly 
inhibited the androgen-responsive LNCaP cell growth by regulating cell cycle and 
androgen-mediated pathway. The present study aimed to evaluate glyceollins’ effect in 
reducing prostate cancer tumor growth in a xenograft model. Androgen responsive 
LNCaP cell and androgen independent PC-3 cell were used to establish cancer cell tumor 
xenograft in animals fed control or glyceollins supplemented diets. An initial delayed 
appearance of tumor was observed in PC-3 xenograft model, however, no difference in 
tumor sizes was observed in LNCaP xenograft. Extrapolation analysis of tumor 
measurements indicated that no difference in sizes was expected for both PC-3 and 
LNCaP tumors at 100 days after injection. Glyceollins showed no effect on androgen 
responsive, proliferation, cell cycle, and angiogenesis genes in tumor and xenobiotic 
metabolism, cholesterol transport, and inflammatory cytokine genes in liver. Glyceollins’ 
low bioavailability (0.054 ± 0.013 µM) might have led to the ineffectiveness in reducing 








Prostate cancer is identified as the most prevalent cancer and the third as a cause 
of cancer deaths in U.S. population in the past two decades, and accounts for 15% of all 
malignant cancer incidences (AACR, 2014; Fitzpatrick, Schulman, Zlotta, & Schroder, 
2009; Palapattu, Sutcliffe, Bastian, Platz, De Marzo, Isaacs, et al., 2005). Many factors, 
including genetics, hormones, race, age, diet, and the environment have been identified to 
be responsible for the initiation and development of prostate cancer. However, the exact 
causes of prostate cancer remain largely unknown, and there is currently no effective cure 
for this disease (Hsing & Chokkalingam, 2006; Violette & Saad, 2012). Therefore, 
developing and validating preventive strategies becomes critical to the control of prostate 
cancer’s occurrence and impact (Meadows, 2012; Umar, Dunn, & Greenwald, 2012). 
Both population and experimental studies have implicated the importance of diet in 
prevention and reduction of cancer, including prostate cancer (Llaverias, et al., 2010; 
Meadows, 2012; Wang, Khor, Shu, Su, Fuentes, Lee, et al., 2012). Vegetables, legumes, 
and fruits are known to be rich in phytochemicals and were found to contribute to a 
decreased risk of cancer (Androutsopoulos, Papakyriakou, Vourloumis, Tsatsakis, & 
Spandidos, 2010; R. Chan, Lok, & Woo, 2009; Willett, 1995). Therefore, food-derived 
products or compounds are of great interest and importance as chemopreventive agents.  
Previous studies indicated a correlation between consumption of soy products in 
Asian population with a decreased incidence of chronic diseases, such as cardiovascular 
disease and cancer (Ahmad, et al., 2008; Azadbakht & Esmaillzadeh, 2008; Clair & 
Anthony, 2005; Hwang, Kim, Jee, Kim, & Nam, 2009). Soy isoflavones, such as 




for disease prevention (Sarkar & Li, 2003; Taku, Melby, Nishi, Omori, & Kurzer, 2011; 
Verdrengh, Jonsson, Holmdahl, & Tarkowski, 2003). Glyceollins are a group of 
phytoalexins, derived from the precursor daidzein, and the biosynthesis of which is 
increased under stress, e.g. UV light, low temperature or fungal infection (Kim, Lim, 
Kim, & Kim, 2012; Zimmermann, et al., 2010). Recent studies have shown glyceollins’ 
inhibitory effect on estradiol-induced proliferation and ERα signaling in breast cancer 
cells and xenograft animal model (Payton-Stewart, et al., 2010; Zimmermann, et al., 
2010). Our previous research found that the glyceollins significantly inhibited the 
androgen-responsive LNCaP cell growth, while glyceollins exert little growth inhibitory 
effects on the androgen independent PC-3 cells. The growth inhibitory effects of the 
glyceollins on LNCaP cells appeared to be due to an inhibition of G1/S progression and 
correlated with an up-regulation of CDKN1A and 1B at mRNA and protein levels. In 
addition, glyceollins treatments led to down-regulated mRNA levels of several androgen-
responsive genes including PSA, supporting a role of glyceollins in androgen-mediated 
pathway (Payton-Stewart, et al., 2009). These findings suggest that glyceollins may 
possess preventative properties towards prostate cancer. However, the exact effect and 
mechanisms remain unclear. 
In this study, the hypothesis that glyceollins can prevent or reduce prostate cancer 
tumor growth in xenograft model was tested. Glyceollins’ effect on androgen responsive 
genes was first determined in-vitro. Then androgen responsive LNCaP cell and androgen 
independent PC-3 cell were used in xenograft model fed formulated rodent diet 
supplemented with or without glyceollins. An initial delayed appearance of tumor was 




in LNCaP xenograft. Extrapolation analysis of tumor measurements indicated that no 
difference in sizes was expected for both PC-3 and LNCaP tumors at 100 days after 
injection. Mass spectrometry analysis revealed that glyceollins’ low bioavailability might 
have led to the ineffectiveness in reducing tumor growth in-vivo. 
 
3.3. Material and methods 
Chemicals and diets. Soy (Asgrow Soybean Seed, Treatment code: 0, 
Germination: 85%, Origin: NC) was acquired from Monsanto Company (St. Louis, MO). 
The fermentation process of soy was modified and standardized in order to ensure the 
elicitation of glyceollins and maximize its concentration. Soy was cut to pieces with a 
food processor and fermented with baking yeast (1% w/w) for 96 h. Glyceollins were 
then purified following previously published methods (Payton-Stewart, et al., 2009). 
Powder AIN-93M diets with or without glyceollins (250 mg/kg diet) were prepared by 
Research Diets (New Brunswick, NJ) and stored at -20 ºC until weekly feedings.  
Cell treatment and gene expression analysis in LNCaP and PC-3 cells. To 
determine the glyceollins’ effect on the attachment of LNCaP and PC-3, cells were plated 
in 6 well plates (Costar, Corning Incorporated, Corning, NY) with glyceollins at the 
indicated concentrations (5, 10, and 25 μM). After 8 h, plates were washed twice with 
1×PBS, attached LNCaP and PC-3 cells were harvested, and total protein was determined 
using BCA Protein Assay (Thermo Scientific Pierce, Rockford, IL). 
To determine the mRNA expression levels of proliferation gene expressions, 
LNCaP cells were cultured in 6 well plates overnight. Glyceollins were added into the 




incubated in PRMI media with 10% fetal bovine serum and 1% antibiotic/antimycotic. 
After 24 h or 48 h, culture media were discarded, and cells were collected.  
RNA isolation and real-time PCR were performed according to the previously 
published protocol (Huang, Fletcher, Niu, Wang, & Yu, 2012). Cells were washed with 
1×PBS and TRIzol reagent was added for total RNA isolation. StrataScript First Strand 
complementary DNA Synthesis kit was used to reverse transcribe complementary DNA. 
Real-time PCR was performed on Applied Biosystems ViiA™ 7 Real-Time PCR System 
using TaqMan Universal PCR Master Mix. The TaqMan gene expression assays were 
acquired from Applied Biosystems (Carlsbad, CA) and used for gene detection. The 
mRNA amounts were normalized to an internal control, TATA-binding protein (Tbp) 
mRNA. The following amplification parameters were used for PCR: 50 °C for 2 min, 95 
°C for 10 min, and 46 cycles of amplification at 95 °C for 15 sec and 60 °C for 1 min. 
Tumor xenograft model. LNCaP and PC-3 human prostate cancer cells were 
obtained from the American Type Culture Collection (Manassas, VA) and grown in 
RPMI-1640 supplemented with 2 mM L-glutamine, 10% Fetal Bovine Serum (FBS), 100 
U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen, Carlsbad, CA) at 37 °C in a 5% 
CO2 atmosphere. Male athymic nude mice (BALB/c nu/nu, 20-22 g, 5-6 weeks old; 
Charles River, Frederick, MD) were individually housed in filter-top cages at the USDA 
BHNRC animal facility and consumed food and fresh tap water ad libitum. Food 
consumption and body weights were recorded twice a week. After an acclimation period 
of 2 weeks, during which mice were fed control AIN-93M diet, the mice were 
randomized into 4 experimental groups, with 12 animals in each group. The animals (24 




later, LNCaP and PC-3 human prostate cancer cell xenografts were established in the 
mice by injection s.c. in the flank (one injection each flank) with LNCaP or PC-3 cells 
(2×106 cells) in 50 µL of phosphate-buffered saline (PBS) and 50 µL Matrigel (BD 
Biosciences, Mansfield, MA). Animals injected with LNCaP cells and fed control diet 
were designated as Group L, and animals fed glyceollins diet as Group LG. Animals 
injected with PC-3 cells and fed control diet were designated as Group P, and animals fed 
glyceollins diet as Group PG.  Cancer preventive efficacy of the treatments was assessed 
twice a week by measuring tumor volume (cm3) calculated as 0.523 x [length (cm) × 
width2 (cm2)] (Hudson, Perkins, Hursting, Young, Kim, Wang, et al., 2012). Mice were 
remained on their respective diets for 8 weeks after cell injection. All animal 
experimental protocols were performed in accordance with the National Institutes of 
Health guidelines and approved by the USDA, ARS, Beltsville Area Animal Care and 
Committee (BAACUC). 
Plasma and tissue collection. Animals were sacrificed at the fourth (PC-3 
xenograft) and eighth (LNCaP xenograft) weeks after tumor injection when tumors 
reached 2-3 cm3 in volume. Animals were anesthetized with CO2 and blood were 
obtained by cardiac puncture with syringes previously rinsed with potassium EDTA 
solution (15% w/v), and plasma was separated after centrifugation at 1500 rpm for 30 
min at 4 ºC. Liver and tumor were collected and quickly frozen in liquid nitrogen and 
stored at -80 ºC. 
Liquid chromatography-mass spectrometry analysis of plasma concentration 
of glyceollins. LC-ESI-MS and LC-ESI-MS/MS analyses were conducted on an Agilent 




Quadrupole Mass Spectrometer (Thermo Scientific, Middletown, VA). Separation was 
performed on an Agilent Eclipse XDB C18 column (4.6 × 150 mm ID, 5 μm). Ten 
microliters was injected onto the column held at 25 °C. The binary mobile phase 
consisted of mobile phase A (water with 0.1% formic acid) and mobile phase B 
(acetonitrile with 0.1% formic acid). The gradient was 0-4 min 30% A to 2% A and hold 
at 2% A for 10 min; 14-16 min 2% A to 30% A and hold at 30% A for 7 min; the flow 
rate was 0.200 mL/min. The UV absorbance detector was set at 285 nm. For positive ion 
LC-ESI-MS and LC-ESI-MS/MS analyses, electrospray parameters were set at the 
following: sheath gas pressure of 60 psi, ionspray voltage of 3500 V, auxiliary gas 
pressure of 15 psi, collision gas pressure of 1.5 mTorr, capillary temperature of 268 °C. 
Declustering potential and collision energy were maintained at -12 V and 16 eV, 
respectively. Parent and product mass scan were performed at 339.000 and 229.042.  
Total RNA isolation, cDNA synthesis and gene expression analysis from liver 
and adipose tissue. To determine the gene expression changes, liver and adipose tissues 
preserved in RNALater were cut into 0.1 to 0.2 g pieces and homogenized using a 
Precellys 24 (Bertin Technologies, Villeurbanne, France). RNeasy Mini Kit and RNeasy 
Lipid Tissue Mini Kit (Qiagen, Valencia, CA, USA) were used for total RNA isolation 
for liver and adipose, respectively. StrataScript First Strand complementary DNA 
Synthesis kit from Stratagene (Santa Clara, CA, USA) was used to reverse transcribe 
complementary DNA. Real-time PCR was performed on an Applied Biosystems ViiA™ 
7 Real-Time PCR System using TaqMan Universal PCR Master Mix and TaqMan® 
Probe-Based Gene Expression assays by Applied Biosystems (Carlsbad, CA, USA). 




Reed, Chen, & Stewart, 2006). TATA-binding protein (Tbp) expression was used as the 
house-keeping gene for calculations. 
Statistical analysis. All end point assays for each sample were conducted in 
triplicate and the average was used for group analysis, data for each treatment group were 
presented as mean ± standard error. Significance level of differences in means was 
detected using one-way ANOVA and Tukey’s test. Statistics analysis was performed 
using IBM SPSS Statistics 19.0 (2010, IBM Corporation, Armonk, NY, USA) or 
Graphpad Prism 6 (2012, Graphpad Software, La Jolla, CA, USA). Statistical 
significance was defined at p ≤ 0.05.  
 
3.4. Results 
Glyceollins’ Effect on Androgen Dependent Pathway in LNCaP Cells. 
Glyceollins, as low as 1 μM, significantly reduced androgen responsive genes PSA and 
NKX3.1 expression in LNCaP cells, 70% and 75% respectively (Fig. 3.1).  
 
Fig. 3.1. Glyceollins’ effect on PSA and NKX3.1 gene expression in LNCaP cells. 






















































Body Weight and Food Intake. There were no difference in body weight or 
body weight gain between any of the diet treatments during the experimental period 
except for the last measurement, in which group LG animals showed a significant higher 
food intake and body weight (Fig. 3.2). Food intake of group L and LG animals 
significantly decreased at the eighth week after injection, as the tumors on the flanks 
started to hinder the movement of the animals. 
 
Fig. 3.2. Body weight and food intake. Animals injected with LNCaP cells and fed 
control diet was designated as Group L, and animals fed glyceollins diet as Group LG. 
Animals injected with PC-3 cells and fed control diet was designated as Group P, and 
animals fed glyceollins diet as Group PG.   
 
 
LNCaP and PC-3 Tumor Growth. Palpable and measureable LNCaP tumors 
were recorded on the fourth week after the injection, and PC-3 tumors were recorded on 
the sixth day after the injection (Fig. 3.3). PC-3 tumor was solid, pale, and no blood 
vessel were observed in the tumor; whereas LNCaP tumor was dark red with dense blood 
vessel. Although control group (L) showed higher tumor volume than the glyceollins 
treatment group (LG), no significant difference in LNCaP tumors size were detected 
throughout the experiment period. On the other hand, PC-3 tumors of glyceollins 
treatment group (PG) were significantly smaller than that of the control group (P). PC-3 

































































tumors grew at a much fast rate and reached 930 and 688 mm3 5 weeks after the 
injection, and LNCaP tumors reached 419 and 266 mm3 9 weeks after the injection. 
 
Fig. 3.3. Tumor growth in LNCaP and PC-3 xenograft. Tumor size was measured twice a 
week. Significant difference in tumor volume between control and glyceollins treatment 
was marked with asterisk (p ≤ 0.05). 
 
 
Extrapolation of tumor volume data to 100 days after injection indicated that no 
difference in of tumor size between the control and treatment groups (Fig. 3.4). LNCaP 
tumors reach similar sizes in control and glyceollins treated animals at around 110 days, 
and PC-3 tumors reach similar at around 75 days. 
 
Fig. 3.4. Extrapolation of LNCaP and PC-3 tumor growth. Extrapolation analysis was 




Attachment Assay of LNCaP and PC-3 Cells. LNCaP and PC-3 cells at the 
same passage (passage 12) as the cells used in the injection were plated with glyceollins 











































































































in the media. After 8 h of incubation, attached cells were harvested and it was determined 
that 25 μM and 10 μM glyceollins reduced attachments of LNCaP and PC-3 in-vitro, 
respectively (Fig. 3.5), lower concentrations did not affect their attachments. 
 
Fig. 3.5. In-vitro LNCaP and PC-3 attachment assay. LNCaP and PC-3 cells were plated 
in 6-well plates with indicated concentration of glyceollins. Attached cells were measured 
by total protein and significant difference between control and glyceollins treatment was 
marked with asterisk (p ≤ 0.05). 
 
 
Glyceollins’ Effect on Gene Transcription in LNCaP Tumors. LNCaP tumors 
were analyzed for the androgen responsive (PSA), proliferation (Ki-67, PCNA), 
apoptosis (Bcl-2, Bax), cell cycle (CDKN1A, CDKN1B) and angiogenesis (VEGF, 
PECAM) genes to determine glyceollins’ effect on these pathways (Fig. 3.6). A 
significant but minor (9%) reduction in PCNA gene expression was observed in tumors 
of glyceollins supplemented animals. No change was observed in the expression of PSA, 
Ki-67, Bcl-2, Bax, CDKN1A/1B, VEGF and PECAM. 




































Fig. 3.6. Expression of Androgen Responsive, Proliferation, Apoptosis, Cell Cycle, and 
Angiogenesis Markers in LNCaP Tumors. Significant difference between control and 
glyceollins treatment was marked with asterisk (p ≤ 0.05). 
 
 
LNCaP tumors were analyzed for inflammatory gene markers (TNFα, IL-1β, IL-
6, COX-2, and EMR1) expressions. No change was observed in inflammatory cytokine 
expressions of TNFα, IL-1β, IL-6, and COX-2, and there was no change in macrophage 


































































































































































































Fig. 3.7. Expression of Inflammatory Markers in LNCaP Tumors. Significant difference 
between control and glyceollins treatment was marked with asterisk (p ≤ 0.05). 
 
 
Proliferation Markers in PC-3 Tumors. PC-3 tumors were analyzed for the 
proliferation marker, Ki-67, to determine glyceollins’ effect on cell proliferation (Fig. 





















































































































Fig. 3.8. Expression of Proliferation Markers in PC-3 Tumors. Significant difference 
between control and glyceollins treatment was marked with asterisk (p ≤ 0.05). 
 
 
Glyceollins’ Effect on Gene Transcription in LNCaP Tumor Animal Livers. 
Gene expressions of phase I and phase II enzymes in livers of LNCaP tumor animals 
were analyzed in this study. No difference in expression levels of CYP1A1, CYP2D10, 



























Fig. 3.9. Expression of CYP450 genes in Livers of LNCaP Tumor Animals. Significant 




























































































Fig. 3.10. Expression of Phase II Enzyme Genes in Livers of LNCaP Tumor Animals. 
Significant difference between control and glyceollins treatment was marked with 
asterisk (p ≤ 0.05). 
 
 
Gene expressions of ABC family transport were analyzed in this study. A 
significant but minor (22%) increase in ABCG5 gene expression was observed in livers 
of glyceollins supplemented animals (Fig. 3.11). No change was observed in the 


















































Fig. 3.11. Expression of Cholesterol Transport Genes in Livers of LNCaP Tumor 
Animals. Significant difference between control and glyceollins treatment was marked 
with asterisk (p ≤ 0.05). 
 
 
Gene expressions of IL-1β, IL-6, COX-2, and TGF-β were analyzed in livers of 
LNCaP tumor animals. No difference in expression levels of these inflammatory markers 






















































































Fig. 3.12. Genes Expressions of Inflammation Markers in LNCaP Tumor Animal Livers. 
Significant difference between control and glyceollins treatment was marked with 
asterisk (p ≤ 0.05). 
 
 
Plasma Concentration of Glyceollins. In animals fed with the control diet, 
glyceollins were undetected in plasma by mass spectrometry. Average concentration of 
glyceollins was determined to be 0.054 ± 0.013 μM in supplemented animals, ranging 
from 0.004 to 0.12 μM. Daily consumption of glyceollins in the diet was calculated to be 
~3.61 μmol, at the end of study, average animal body weight was 20.04 g, and mouse has 
a blood volume of 79 mL/kg (Drexelmed.edu). Thus, about 2.3% of ingested glyceollins 














































































































































































































































This study examined the anti-tumor effects of glyceollins on androgen 
responsive LNCaP and androgen independent PC-3 human prostate cancer cells in-
vivo. An initial delayed appearance of tumor was observed in PC-3 xenograft model, 
however, no difference in tumor sizes was observed in LNCaP xenograft. 
Extrapolation analysis of tumor measurements further support that no difference in 
tumor sizes between the diet group for both PC-3 and LNCaP tumors even at 100 
days after injection. In-vitro analysis showed that, glyceollins was able to 
significantly reduce the mRNA expression of androgen responsive genes PSA and 
NKX3.1 in LNCaP prostate cancer cells at as low as 1 μM (Fig. 3.1). This 
observation was consistent with our previous report, in which glyceollins was able to 
inhibit LNCaP cell growth through inhibition of G1/S progression and up-regulation 
of CDKN1A/1B (Payton-Stewart, et al., 2009). However, no effect was observed in 
LNCaP tumor growth in xenograft model (Fig. 3.3) and androgen responsive genes 
(Fig. 3.6). The disconnection between in-vitro and in-vivo data may be explained by 
the low bioavailability of glyceollins in the athymic nude mouse model. Analysis of 
plasma revealed that only 2.3% of glyceollins contained in the diet was absorbed into 
the circulation, achieving 0.054 ± 0.013 μM in the blood stream. In this study, 
glyceollins were able to affect the androgen responsive genes in-vitro at as low as 1 
μM, while, in our animal model, oral intake of 250 mg/kg glyceollins merely 
achieved 0.054 ± 0.013 μM in circulation, which is about 5% of the concentration 




In our previous study, hamster fed with 250 mg/kg glyceollins diet achieved 
0.14 ± 0.025 μM glyceollins in circulation, and cholesterol-lowering effect was 
observed. At the same supplementation level, hamster absorbed 19% glyceollins from 
diet, whereas mouse only absorbed 2.3%. Two factors may have significantly affected 
the bioavailability of glyceollins in the animal models: 1) species differences between 
hamster and athymic nude mouse; and 2) composition of a diet, such as fat content. 
Species differences exist in animal models, which can significantly affect the 
bioavailability of exogenous compounds, such as phytochemicals and drugs (Gad, 
2007). Thickness and length of the small intestine, gut transit time, and differences in 
facilitated or active transport all play a role in gastrointestinal absorption of 
exogenous compounds. Blood flow to organs, extent and avidity of compounds 
binding to plasma proteins, and the extent of clearance of the compounds can affect 
the distribution process (Gad, 2007). Distinct xenobiotic metabolism systems (Phase I 
and Phase II enzymes) in different animal models can also impact the metabolism and 
retention of specific compounds (Liska, 1998). Thus, physiological differences in 
athymic nude mouse and hamster may significantly affect the bioavailability of 
glyceollins. On the other hand, the composition of a diet may also affect the uptake of 
glyceollins in the animals. Hamsters were fed high diet (36% calorie from fat) 
supplemented with 250 mg/kg glyceollins, while low fat diet (10% calorie from fat) 
was used in the mouse study (Huang, Xie, Boue, Bhatnagar, Yokoyama, Yu, et al., 
2013). The differences in fat contents may affect the absorption of glyceollins in the 
diet. Further study is needed to understand the extent of the impact of animal models 




This study indicated that glyceollins supplementation could delay the initial 
appearance of PC-3 tumor (Fig. 3.3). PC-3 is an androgen independent cell line, and 
analysis of proliferation factor Ki-67 in the PC-3 tumor showed no change of 
expression, thus, the delayed appearance of tumor might be the result of reduced 
attachment of PC-3 cells. In-vitro analysis did show reduced cell attachment, 
however, a significant reduction was only observed at concentration higher than 10 
μM. Considering the limited bioavailability and plasma concentration of glyceollins, 
10 μM was a concentration unlikely to achieve in-vivo. 
Inhibition of PCNA, a cell proliferation factor, was observed in glyceollins 
supplemented LNCaP tumor. However, the minor change may be of little biological 
significance, and no difference was detected in LNCaP tumor growth and other 
transcriptional factors. An increase of ABCG5 in LNCaP tumor animal livers was 
observed, which indicated glyceollins may facilitate the efflux of cholesterol from the 
liver through ABCG transport. In our previous study in hamster, ABCG5 was reduced 
in glyceollins treated animals compared to high-fat diet animals (Huang, et al., 2013). 
The discrepancy may result from the difference in diet compositions and 
physiological conditions. Hamster was fed high fat diet while the mouse was fed low-
fat diet. The increased consumption of dietary fat and cholesterol led to an increase in 
circulating and hepatic lipid and cholesterol in hamster. The decreased of ABCG5 in 
the hamster model was concluded to be the consequence of reduced circulating and 
hepatic cholesterol (Huang, et al., 2013). 
Based on the previous observation in cell model, the present study aimed to 




models. The growth inhibition effect in-vitro was not observed in the xenograft 
models, regardless of their androgen responsiveness. The ineffectiveness of 
glyceollins in-vivo might result from the limited bioavailability of glyceollins in 
athymic nude mouse model through ingestion with low-fat diet. Further study in the 
attempt to increase the bioavailability and elucidate high-fat diet’s effect on 
absorption of glyceollins is warranted to evaluate glyceollins’ potential in prevention 





Chapter 4. Effect of Glyceollins on gut Microbiome  
 
4.1. Abstract 
Microbiome has emerged as an important and integral part of the human 
physiology with a significant role in human health and disease. Diet and dietary 
components have been shown to shape and alter the population and composition of 
human gut microbiome. A relation between soy consumption and change in 
microbiome has been reported previously. However, the precise component(s) 
contributed to soy’s effect on microbiome remain unclear. The current study aimed to 
evaluate the effect of glyceollins, a group of phytoalexin isolated from soy, on the gut 
microbiome in animal models. Fecal and cecal samples collected from mouse feeding 
studies were analyzed for microbial population and composition. Glyceollins 
supplementation did not alter gut bacteria groups in cecal sample examined in this 
study. Glyceollins significantly affected total Enterobacteriaceae and Ruminococcus 
population in fecal samples collected at 24 h, indicating the impact and importance of 
time of collection in interpreting gut microbiome data in fecal analysis.  
 
4.2. Introduction 
Research in human microbiome has demonstrated that microbial cells (~1014 
cells) outnumber human cells by about 10 times, which makes it a very large and 
complex ecosystem between the residing microorganisms and human body (Hattori & 




Bacteroidetes and Firmicutes are the dominant phyla and account for over 90% of gut 
microbiome in mouse and human, with Ruminococcus, Lactobacillus and Prevotella 
being the major families or genera in these phyla (Eckburg, Bik, Bernstein, Purdom, 
Dethlefsen, Sargent, et al., 2005; Frank, Amand, Feldman, Boedeker, Harpaz, & 
Pace, 2007; Ley, Backhed, Turnbaugh, Lozupone, Knight, & Gordon, 2005; Ley, 
Peterson, & Gordon, 2006). Researches have shown a correlation of increase in 
Firmicutes to Bacteroidetes ratio to an increase in energy harvesting from diet and the 
pathology of obesity (Turnbaugh, Hamady, Yatsunenko, Cantarel, Duncan, Ley, et 
al., 2009; Turnbaugh, Ley, Mahowald, Magrini, Mardis, & Gordon, 2006; 
Turnbaugh, Ridaura, Faith, Rey, Knight, & Gordon, 2009). High fat diet was shown 
to induce an increase in Lactobacillus, and it was also involved in simple sugar 
degradation (Guarner & Malagelada, 2003; Zeng, Liu, Jackson, Yan, & Combs, 2013; 
Zhao, et al., 2011). Ruminococcus and Prevotella were shown to be involved in 
polysaccharides metabolism, especially fiber, in the gastrointestinal tract (Walker, et 
al., 2011; Wu, et al., 2011). More importantly, Enterobacteriaceae, Akkermansia and 
Bifidobacteria have been shown to be involved in energy metabolism and balance, 
and an increase in carbohydrate intake was shown to elevate Enterobacteriaceae and 
Bifidobacteria population, while Akkermansia population was negatively associated 
with consumption of polysaccharides (Amar, Burcelin, Ruidavets, Cani, Fauvel, 
Alessi, et al., 2008; Backhed, et al., 2004; Sonoyama, Fujiwara, Takemura, 
Ogasawara, Watanabe, Ito, et al., 2009; Turnbaugh, Baeckhed, Fulton, & Gordon, 




correlate positively with cholesterol intake and metabolism (Martinez, Wallace, 
Zhang, Legge, Benson, Carr, et al., 2009). 
The link between long-term dietary pattern and chronic diseases has been well 
documented (Galland, 2010; Tyrovolas & Panagiotakos, 2010; WHO/FAO, 2002), 
and the gut microbiome forms the interface between diet and human body (Cho & 
Blaser, 2012). The interaction between bacteria and human cells is central to the 
protective role of intestinal commensal bacteria for maintenance of health (Brestoff & 
Artis, 2013). Putative effects of microbiome on pathology or prevention of metabolic 
diseases, such as obesity, diabetes, and cardiovascular disease are mounting attention 
in recent years (Cani, 2013). Although the exact influence and mechanism remains 
unknown, previous studies have gathered evidence that human microbiome may 
affect human development, physiology, immunity, and nutrition (Dethlefsen, McFall-
Ngai, & Relman, 2007). Clinical trials and comparisons of intestinal microbiomes 
between diseased and healthy subjects have identified biomarkers associated with 
inflammation and functional metagenomic changes (Karlsson, et al., 2013). Recent 
studies demonstrated that the composition of the microbiome, along with its gene 
expression and functional metabolic pathways, could change rapidly when animals 
were switched from low-fat to high-fat diets (Turnbaugh & Gordon, 2009; 
Turnbaugh, Ridaura, Faith, Rey, Knight, & Gordon, 2009). Hence, understanding the 
interaction between diet components and microbiome may be a critical part in 
studying their influence on human health.  
A relation between soy consumption and change in microbiome has been 




overweight and obese men including a potentially beneficial alteration of the 
Firmicutes to Bacteroidetes ratio (Fernandez-Raudales, Hoeflinger, Bringe, Cox, 
Dowd, Miller, et al., 2012). However, the precise component(s) contributed to soy’s 
effect on microbiome remain unclear. Phytoalexins are a group of phytochemicals 
induced by stress factors, such as fungal and bacterial infection, wounding, freezing 
and UV light exposure (Darvill & Albersheim, 1984). Glyceollins are phytoalexins 
accumulated in stressed soy to defend the plant from bacteria and fungi infection 
(Schmidt, Parniske, & Werner, 1992), and previous researches have reported 
glyceollins’ in-vitro anti-bacterial activity (Fett & Osman, 1981; Tzi, Ye, Wong, 
Fang, Chan, Pan, et al., 2011).  Therefore, we hypothesize that phytoalexin, such as 
glyceollins, may contribute to soy’s effect on the microbiome.  
In our literature review, we found one critical and unresolved problem in 
microbiome research appeared to be variable collection time of the fecal sample 
between studies. There appeared to be a wide discrepancy in control of fecal sample 
collection procedure and time among human and animal model studies. Some studies 
used instructions or laboratory protocol to guide the participants to collect fecal 
samples (David, et al., 2014; Karlsson, et al., 2013; Matsuki, Watanabe, Fujimoto, 
Takada, & Tanaka, 2004), while others did not specify the collection procedure 
(Eckburg, et al., 2005; Walker, et al., 2011; Wu, et al., 2011; Zimmer, et al., 2012). 
Most reports did not mention the collection time point in terms of length of time 
elapsed after excretion. A previous study indicated that the fecal microbiome was 
stable over a 72 h period (Roesch, Casella, Simell, Krischer, Wasserfall, Schatz, et 




could rapidly alter microbiome within 24 h (David, et al., 2014; Li, Wu, Baldwin, Li, 
& Li, 2012). Hence, further study warranted to further elucidate the stability of the 
fecal microbiome and optimal collection time. 
The primary aim of this study is to evaluate glyceollins’ effect on the gut 
microbiome in a mouse model. The secondary goal is to compare fecal and cecal 
samples microbial population and composition. Lastly, we seek to evaluate the impact 
of collection time on the fecal microbiome. 
 
4.3. Materials and methods 
Mouse diet and feeding. Male athymic nude mice (BALB/c nu/nu, 20-22 g, 
5-6 weeks old; Charles River, Frederick, MD) were fed control AIN-93M diet and 
AIN-93M supplemented with 250 mg/kg glyceollins (12 animals each group). Mice 
were remained on their respective diets for 10 weeks. At the end of the tenth week, 2 
h and 12 h fecal samples were collected from the bottom of the cage. At the time of 
animals sacrifice, 24 h fecal samples were collected from the bottom of the cage, and 
cecal samples were collected from the ceca, flash frozen in liquid nitrogen and kept at 
-80 °C. 
Gut microbiome analysis. Microbial DNA will be extracted using QIAamp 
DNA Stool Mini Kit from Qiagen following manufacturer’s protocol. Briefly, 100 mg 
of fecal sample will be weighed and placed in a 2 mL tube, homogenized with 
Precellys (Bertin Technologies, France). DNA will be eluted from the column with 
200 μL AE buffer. The concentration of DNA elution will be determined by its 




ng/mL. Real-time PCR was performed on an Applied Biosystems ViiA™ 7 Real-
Time PCR System using Fast SYBR Green Master Mix by Applied Biosystems 
(Carlsbad, CA). A reaction system of 10 μL SYBR® Green Real-Time PCR Master 
Mix, 0.25 μL 500 nM custom-made oligo primers, 4.5 μL water and 5 μL DNA was 
used. Total bacteria were measured using primers detecting sequence universal in 91 
bacteria species (Parnell & Reimer, 2012). Primers specific for Bifidobacteria 
(Parnell & Reimer, 2012), Lactobacillus (Parnell & Reimer, 2012), Akkermansia 
(Parnell & Reimer, 2012), Prevotella (Parnell & Reimer, 2012), Enterobacteriaceae 
(Parnell & Reimer, 2012), Ruminococcus (Wang, Bose, Kim, Hong, Kim, Kim, et al., 
2014), Bacteroidetes (Wang, et al., 2014), Firmicutes (Wang, et al., 2014) were used 
to determine the population of respective microorganisms. Primer sequences are 
listed in Table 4.1. The following amplification parameters were used for PCR: 50 °C 
for 2 min, 95 °C for 10 min, and 46 cycles of amplification at 95 °C for 15 sec and 60 






Table 4.1. Sequence of Real-time PCR Primers 





























Statistical analysis. All end point assays for each sample were conducted in 
triplicate, and the average was used for group analysis, data for each treatment group 
were presented as mean ± standard error. Significance level of differences in means 
was detected using one-way ANOVA and Tukey’s test. Statistics analysis was 
performed using IBM SPSS Statistics 19.0 (2010, IBM Corporation, Armonk, NY, 
USA) or Graphpad Prism 6 (2012, Graphpad Software, La Jolla, CA, USA). 





Comparison of Cecal Microbiome in Animals Fed Control or Glyceollins 
Diet. We determined the relative bacterial abundance in cecal samples. No change 
was observed in selected bacteria species examined after 10 weeks of glyceollins 
supplementation as compared to the control diet (Fig. 4.1). Although an average of 
45% decrease and 62% increase in Bifidobacteria and Akkermansia population, 
respectively, were observed in cecal sample (Fig. 4.1), due to the large individual 
difference in bacteria population, no statistical significance was detected. 
 
Fig. 4.1. Cecal microbiome in mouse consuming control or glyceollins supplemented 
diet. Comparisons were made between control and glyceollins supplemented diet, and 
presented as percent change ± SE. Statistical significance was defined at p ≤ 0.05 and 
marked with asterisk. 
 
 
Temporal Change of Fecal Microbiome Population in Animals Fed 























microbiome analysis, a temporal comparison of fecal samples collected at 2, 12 and 
24 hours after changes of bedding were analyzed for their microbiome content. No 
significant change in the microorganism population was observed between the 2 h 
and 12 h fecal samples of the two diet groups (Fig. 4.2). Although an average of 
506% and 264% increases in Akkermansia were observed at 2 h and 12 h, 
respectively, no statistical significance was detected due to large inter animal 
differences. Significant increases of Enterobacteriaceae (96%), and Ruminococcus 
(708%) were observed in fecal samples collected over a 24 h period (Fig. 4.2). 
Akkermansia showed the most variance between individual animals in cecal or fecal 
samples. Average Akkermansia in the 24 hours fecal samples from glyceollins treated 
group was 1000-fold higher comparing to that of the control group. However, the 






Fig. 4.2. Fecal microbiome in mouse consuming control or glyceollins supplemented 
diet accumulated in 2 h, 12 h, and 24 h. Comparisons were made between control and 
glyceollins supplemented diet, and presented as percent change. Statistical 

















































































Comparison of Cecal and Fecal Microbiome. Total bacteria in cecal and 
fecal samples were further compared (Fig. 4.3). Cecal samples were designated as 0 
hour and compared with the 2, 12, and 24 hours fecal samples. Total bacteria 
population from animals consumed control diet showed no significant change over 24 
h period. On the other hand, there was a significant decrease in total bacteria in fecal 
samples from animals fed with glyceollins supplemented diet at 24 h (Fig. 4.3). The 
decreased total bacteria in glyceollins supplemented animal feces were also 
significantly lower than that in control animal feces. 
 
Fig. 4.3. Changes of total bacteria in mouse consuming control or glyceollins 
supplemented diet over a 24 h period time course. Relative bacteria levels were 
normalized to cecal bacteria. Comparisons were made between control and 
glyceollins supplemented diet. Statistical significance was defined at p ≤ 0.05 and 
marked with asterisk. 
 
Over a 24 h period, fluctuations in bacteria population were observed (Fig 4.4) 
and samples from control or glyceollins diet groups showed a similar trend of change 
(Fig. 4.4). In animals fed a control diet at the first 2 h after excretion, an increase in 
Total Bacteria






























population was detected in Lactobacillus. By contrast, population of Bifidobacteria, 
Akkermansia, Prevotella, Ruminococcus, Bacteroidetes, and Firmicutes remained at 
the same level. A decrease in Enterobacteriaceae was observed (Fig. 4.4). At the 12 h 
time point, increased bacteria population were observed for Lactobacillus, with 
Prevotella, Ruminococcus, Akkermansia, Bacteroidetes. Firmicutes remained at the 
same level, and decreases in population were observed in Bifidobacteria and 
Enterobacteriaceae (Fig. 4.4). At 24 h, population of Bifidobacteria, Prevotella, 
Enterobacteriaceae, Bacteroidetes, and Firmicutes were lower than that in 0 hour 
(cecal) samples, while Lactobacillus, Akkermansia, and Ruminococcus remained at 
the same level as that in 0 hour (cecal) samples (Fig. 4.4). In samples from animals 
fed the glyceollins diet, similar trend of changes as that of the control diet animals 
were observed except that no significant change was observed in Bifidobacteria at 12 





Fig. 4.4. Changes of microbiome in mouse consuming control or glyceollins 
supplemented diet over a 24 h period time course. Relative bacteria levels were 
normalized to cecal bacteria. Comparisons were made between 0 h cecal samples and 
fecal samples at different time points, and statistical significance was defined at p ≤ 
0.05 and marked with asterisk.  stands for control group and stands for glyceollins 
supplemented group. 




























































































































































































There are several interesting observations in our study on the gut microbiome. 
In this study, we first evaluated glyceollins’ effect on the gut microbiome in cecal 
samples. Soy has been reported to alter microbiome, however, the precise active 
component has been not identified (Fernandez-Raudales, et al., 2012). This is the first 
report on the effect of a specific soy component on the gut microbiome. Despite the 
phytoalexin properties of glyceollins, we did not observe any significant change in 
microbiome as compared to the cecal samples from animals fed a control diet. 
Glyceollins have been reported to possess anti-bacterial activities and growth 
inhibitory effect on some bacteria. Previous study has shown that glyceollins 
inhibited growth of certain strains of Bacillus, Staphylococcus, and Xanthomonas 
(Fett & Osman, 1982). However, the bacteria strains determined in this study did not 
match the ones tested in the previous study, and the exact species or stains affected by 
glyceollins require further elucidation.  
Another interesting observation was fecal samples collected from animals 
consuming a glyceollins supplemented diet showed significant changes over a 24 h 
period (Fig. 4.3). A sharp decrease in total bacteria after 24 h was observed in the 
glyceollins supplemented group, and was significantly less than that of the control 
diet group. Total bacteria in fecal samples from animals fed control diet did not 
change significantly over a 24 h period. Therefore glyceollins appeared to affect total 
bacteria, albeit after 24 h outside of gut. Hence, the sample collecting process (time of 
collection) couple with a treatment might in part contribute to an observed change in 




Previous study has shown that the fecal microbiome was relatively stable after 
excretion to 72 h, and the change in bacterial communities was about 10% within 24 
h (Roesch, et al., 2009). Interestingly, our study showed that specific groups of fecal 
bacteria changed significantly as early as 2 h. Species specific changes in bacteria 
were observed in this study (Fig. 4.4), which might result from 1) compositions of 
aerobic and anaerobic bacteria in each phyla, families or genera, or 2) the roles of 
specific bacteria in energy metabolism and balance of diet-derived component. 
Lactobacillus and Enterobacteriaceae showed significant increase and decrease, 
respectively, comparing to the cecal microbiome (Fig. 4.4). Cecal samples were 
directly collected from ceca dissected from the animals and immediately frozen in 
liquid nitrogen. Thus, cecal microbiome is likely to be more reflective of the gut 
microbiome in-vivo, while the fecal microbiome was subject to environmental 
factors, such as oxygen exposure. Gut microbiome are composed of aerobic and 
anaerobic bacteria, with anaerobic bacteria being the predominant population. 
Firmicutes are facultative anaerobic and Lactobacillus is microaerophilic (Ichimura, 
1962), which can survive and grow with or without oxygen. Majority of 
Enterobacteriaceae are anaerobic, and Bifidobacteria, Ruminococcus, Bacteroidetes, 
and Prevotella are strictly anaerobic (Evaldson, Heimdahl, Kager, & Nord, 1982; 
Janssen, 1991; Mahowald, Rey, Seedorf, Turnbaugh, Fulton, Wollam, et al., 2009; 
Walker, et al., 2011). Thus, exposure to oxygen may reduce the growth or affect the 
survival of anaerobic bacteria (Evaldson, Heimdahl, Kager, & Nord, 1982; Peterson, 
1997). However, no precise pattern of change in specific bacteria population could be 




according to our finding, the influence of collection time on the fecal microbiome 
cannot be neglected, and if possible, cecal samples should be used to assess the gut 
microbiome in animal study. 
The oxidation and fermentation of diet-derived fecal components might shift 
the energy metabolism of microbiome and affect their population, leading to an 
increase or decrease of specific bacteria (Albenberg & Wu, 2014; David, et al., 2014). 
AIN-93M diet used in this study was a casein-based diet, which could preferentially 
support the growth of Lactobacillus (Zhang, Ren, Zhao, Zhao, Xu, & Zhao, 2011). 
Lactobacillus was also known to be involved in lipid and simple sugar metabolism 
(Guarner & Malagelada, 2003; Zhao, et al., 2011), and the increase of Lactobacillus 
would lead to faster degradation of lipid and carbohydrate in the feces. Bifidobacteria 
and Enterobacteriaceae were also active in metabolizing polysaccharides (Backhed, et 
al., 2004; Turnbaugh, Baeckhed, Fulton, & Gordon, 2008; Turnbaugh & Gordon, 
2009). The increased degradation of polysaccharides by Lactobacillus might have led 
to the decrease in population of Bifidobacteria and Enterobacteriaceae. 
Trend of changes were observed in several species at all time points, for 
example, 2, 6, 4, and over 1200 folds increase were observed in Akkermansia at 0, 2, 
12, and 24 h, respectively (Fig. 4.1), however, no statistical significance was detected. 
This appeared to result from the huge individual differences between animals in this 
study. Akkermansia was relatively abundant and readily detected in fecal 
microbiome. The exact reason of such discrepancy is not clear. Therefore, the 
consistency of gut microbiome between individual animals is critical to controlling 




developed by transplanting gut microbiome from a single human donor into germ-
free mice (from same litter), appeared establish consistent microbiome in 
experimental animals (Gootenberg & Turnbaugh, 2011; Turnbaugh, Baeckhed, 
Fulton, & Gordon, 2008). The animals used in our study were from an identical 
genetic background (BALB/c nude mouse, strain: CAnN.Cg-Foxn1nu/Crl inbreed), 
raised in the same laboratory environment, and fed rodent chow diet. We believe that 
diversity in the gut microbiome would mimic more of a real life situation and suggest 
that, in human population, the microbiome may be more challenging to dissect.  
In summary, this study examined the effect of dietary intake of glyceollins on 
major phyla, families and genera of microbiome. However, no effect was observed 
for glyceollins on the microbiome under our experimental conditions. Change in 
microbiome can occur to specific species (Turnbaugh, Baeckhed, Fulton, & Gordon, 
2008), and a more global investigation using metagenomic techniques may be 
necessary to pinpoint the specific change in gut microbiome induced by glyceollins 
treatment. Time of fecal collection could play an important role in the outcome of 







It is promising and important to investigate soy’s health promoting potential 
as an important agriculture commodity. The present study focused on characterizing 
the soy-derived phytoalexins glyceollins’ bioactivities in alleviating cholesterol 
dysregulation, prevention of prostate cancer, and regulating gut microbiome. 
Glyceollins supplementation in high-fat diet was shown to significantly reduce 
circulating and hepatic cholesterol, as well as hepatic inflammatory cytokine 
expressions. Glyceollins’ effects in preventing prostate cancer and regulating gut 
microbiome were not observed in our experimental condition, however, further study 
may be performed to conclude glyceollins biological efficacies.  
This project provided scientific evidence for the health beneficial effects of 
the readily accessible soy phytochemicals, and may promote the use of soy as healthy 





Future perspective  
Molecular mechanism of glyceollins’ cholesterol-lowering and anti-
inflammatory effect and glyceollins’ long-term effect on metabolic disorder induced 
by western style diet may be investigated in future studies. The in-vivo absorption, 
distribution and metabolism of glyceollins upon ingestion need to be characterized to 
pinpoint glyceollins’ molecular target(s). Deep sequencing and metabolomic tools 
may be used to elucidate glyceollins’ mechanism of actions at transcriptional and 
translational levels. 
Improvement of glyceollins’ bioavailability may enhance glyceollins’ 
biological efficacy, including anti-tumor effect. Modification of diet formulation and 
delivery mechanisms may help to increase the absorption of glyceollins and prevent 
the degradation or metabolism of glyceollins in the gastrointestinal tract or in the 
liver.  
Glyceollins may affect specific group(s) or species of gut microorganisms in 
the gut and may induce temporal change(s) in gut microbiome. Metagenomic tools 
can be used to reveal the specific change(s) in gut microbiome and multiple time 
points may be studied and correlated to the health outcomes in the animals to 
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